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ABSTRACT 
 
 The work presented in this dissertation focuses primarily on the role of FMRP, the fragile 
X mental retardation protein and its role in translational regulation.  More specifically, I began 
my studies trying to understand the role of FMRP in the nucleus.  This work is novel and 
interesting because the nuclear role of FMRP has not been widely studied.  FMRP is an RNA 
binding protein that is important for normal neuronal development and maturation as well as 
proper cognitive development as the lack of FMRP results in fragile X syndrome (FXS).  I next 
move out of the nucleus and study the role of FMRP and translation in the cytoplasm.  This work 
elaborates on a novel FMRP associated protein, putative RNA helicase MOV10 
 Chapter 1 begins with an introduction to fragile X syndrome as well as a current literature 
review of the fragile X field.  I introduce the history of fragile X syndrome and the 
characteristics of the syndrome as well as introducing the key player: FMRP.  FMRP is an 
interesting protein because it has several RNA binding domains as well as several post 
translational modifications.  Despite all that is currently known about FMRP, there is still a large 
gap in understanding about how these modifications act as guides for specific RNA targeting and 
binding.   
 My first project outlined in Chapter 2 focuses on the role of FMRP in the nucleus.  FMRP 
contains both a Nuclear Localization Sequence (NLS) as well as a Nuclear Export Sequence 
(NES), however how FMRP enters the nucleus is unclear because of its non-canonical NLS.  I 
demonstrate that FMRP enters the nucleus and that it requires Tap/Nxf1 for efficient export from 
the nucleus.  Additionally, I use the Xenopus laevis oocyte system to demonstrate that FMRP is 
indeed present along nascent mRNA transcripts suggesting that FMRP enters the nucleus and 
can target newly transcribed RNAs.   
 Next, in Chapter 3, I focus on a novel FMRP associated protein, MOV10.  MOV10 is a 
putative RNA helicase that associates with FMRP.  I demonstrate that MOV10 and FMRP 
associate in a salt and RNA dependent manner and that the two proteins exist in tissue in 
similarly sized granules suggesting a cellular interaction.  We also determined that FMRP 
requires MOV10 to recruit a number of brain specific mRNAs and that both FMRP and MOV10 
bind G quadruplex structures specifically. Using iClip, we identified MOV10 specific mRNA 
targets as well as identifying binding sites of MOV10.  We also found that Ago2 binding sites 
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influenced the fate of MOV10 clip targets, suggesting a role of MOV10 acting as a facilitator or 
inhibitor of miRNA mediated regulation depending on proximity to Ago2 binding sites.  
 Chapter 4 develops a novel single molecule study directed towards understanding how 
MOV10 behaves as a helicase.  I generated mRNA constructs to study G quadruplex forming 
RNA sequences at the single molecule level and establish that sc1and sc1 mutant RNAs behave 
different in salt solutions.  In addition to studying sc1 and sc1 model RNAs, I expanded the study 
to encompass hASH1, a recently identified FMRP mRNA target that contained tandem GQ 
sequences near the 5’ cap, and also PSD-95, a well established FMRP target.  Through the 
efforts of this chapter, it will be possible to continue to further elucidate the behavior of MOV10 
on target mRNAs identified through the iCLIP studies.  
 In Chapter 5, I explore the role of MOV10 in the 5’UTR of mRNA targets.  Chapter 3 
focused more on the role of the 3’UTR and miRNA mediated translational regulation and mRNA 
stability.  From the data generated from the iCLIP studies, we found a number of genes that are 
bound by MOV10 in the 5’UTR.  Using hASH1 as a model mRNA target based on previously 
published work on FMRP and hASH1 translation, we found that upregulation of hASH1 by 
FMRP is dependent on the presence of MOV10.  These studies demonstate that MOV10 may 
also play a significant role in translation through the 5’UTR through a mechanism that is 
independent of the miRNA pathway.  
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Chapter 1. Fragile X Mental retardation protein: Past, present and future 
 
This chapter has been previously published in part as “Fragile X Mental Retardation protein: Past, 
present and future” (Curr Protein Pept Sci. 2012 Jun;13(4):358-71).  Permission to reprint the 
material has been provided by the publisher.  
 
1.1 Fragile X Syndrome 
 
 Fragile X Syndrome (FXS) was first described by Martin and Bell after characterizing 
families with males with intellectual disability [1]. In 1969, Herbert Lubs observed a constriction 
on the X chromosome in males with Martin-Bell syndrome.  These constricted sites were called 
“fragile” sites on the X chromosome due to their propensity to break [2].  However, this 
constriction was not a reliable predictor of Martin-Bell syndrome until Southerland and 
colleagues described a way to increase the occurrence of the fragile site by using folate-deficient 
media [3].  The possibility that a gene existed within this fragile site led to the cloning and final 
discovery of the fragile X mental retardation gene, FMR1, in 1991. The source of the fragile site 
was a CGG repeat expansion in the 5’ Untranslated Region (UTR) of the FMR1 gene [4]. The 
gene product of FMR1, the Fragile X Mental Retardation Protein FMRP, was characterized as an 
RNA binding protein soon after [5]. 
 Expansion of the CGG repeat in the first exon of the FMR1 gene is the cause of FXS--
one of the first trinucleotide repeat disorders described (reviewed in [6]).  It is now known that 
there are several other disorders caused by trinucleotide repeat expansions in both UTRs, as in 
myotonic dystrophy, and in coding regions, such as Huntington’s disease and a number of 
spinocerebellar ataxias [6]. The FMR1 gene is 38 kb in size, containing 17 exons and encoding a 
4.4 kb mRNA transcript containing a G-quadruplex in the coding region [7]. The average CGG 
repeat length is 6-44 with a mode of 30 [8].  Repeats within that range are stably transmitted 
from generation to generation.  Grey zone alleles with repeats between 45-54 and premutation 
alleles with 55-200 repeats are highly unstable and prone to expansion during maternal 
transmission [8].   
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Mechanisms of expansion 
 The CGG repeat expansion occurs predominantly during maternal meiosis, although the 
reason for this gender bias is currently unknown [8]. Three potential mechanisms for repeat 
expansion have been proposed including recombination, replication, and repair (reviewed in [9]). 
It is thought that the trinucleotide repeat forms a stable secondary structure during replication, 
causing the DNA polymerase to skip or stall during replication, leading to repeat expansion. The 
leading and lagging strands form hairpin structures with Watson Crick base pairing or 
mismatched pairing based on the sequence, which would ultimately result in compromised DNA 
repair [10-12]. Recently, a crystal structure of the CGG repeat has been solved, demonstrating 
the complex nature of the CG and  GG base pairing and stacking to form a stable pseudo helix 
[13].  This highly stable structure may stall the DNA polymerase at the replication fork, causing 
problems with re-initiation and repair [11]. During DNA replication, the CGG repeat causes 
slipping of the three-way DNA junction, which causes the repair machinery in the cell to 
continuously add a few repeats, gradually expanding the repeat over time [10]. Once the number 
of repeats exceeds 200, the FMR1 gene is abnormally hypermethylated, causing chromatin 
condensation and subsequent gene silencing. Thus, individuals with FXS express no FMR1 
mRNA and consequently, no FMRP. 
 
Other causes of FXS 
 While repeat expansions are the most common cause of FXS, other mutations within the 
gene that compromise protein function or perturb gene expression will also lead to the syndrome.  
One of the most striking examples of fragile X syndrome due to a point mutation is the 
isoleucine to asparagine (I304N) substitution in the KH2 domain [14]. Recent studies by Collins 
and colleagues used massively parallel sequencing of developmentally delayed males without 
CGG repeat expansion to discover mutations in the fmr1 promoter region as well as a novel 
variant, R138Q, present within the nuclear localization sequence of the protein [15].  
Interestingly, this residue is highly conserved among many species. Additional studies by Collins 
and colleagues found a deletion in the fmr1 gene beginning 220 bases upstream of the CGG 
repeat, spanning 355 bases into the second codon of the FMR1 coding sequence [16].  This 
mutation resulted in the absence of FMRP expression, thus resulting in FXS without repeat 
expansion.  These mutations demonstrate the necessity for expression of a fully functional 
3 
 
protein--one that can shuttle and localize properly, as well as bind and recognize mRNA properly. 
The consequences of improper localization and RNA binding will be discussed in more detail 
below.   
 
1.2 Fragile X premutation syndromes 
 
 The prevalence of premutation carriers in the population is about 1:130-250 for females 
and about 1:800 males [17].  While functional FMR1-encoded protein, FMRP, is produced in 
these individuals, premutation carriers are also expressing an FMR1 transcript with an expanded 
CGG repeat. Premutation alleles can produce two distinct syndromes including a parkinsonian-
like tremor-ataxia referred to as fragile X-associated tremor/ataxia syndrome (FXTAS) and 
premature ovarian insufficiency, termed fragile X-associated premature ovarian insufficiency 
(FXPOI). FXTAS was first described in 2001 in male premutation carriers as a late onset 
neurodegenerative disorder (reviewed in [18]).  Individuals diagnosed with FXTAS develop 
progressive intention tremor and cerebellar gait ataxia as well as memory deficits and emotional 
changes [19, 20]. Females generally present less frequently and with less severe clinical 
phenotypes than males who have FXTAS [21]. In FXPOI, up to 23% of women reach 
menopause prior to the age of 40, and even as early as in the teenage years, in contrast to the 
general population where the risk is about 1% [22].  The extent of ovarian dysfunction depends 
on the length of the repeat expansion as well as the age of the individual, increasing in severity 
with increasing repeat length and progressing age [23]. 
 The mechanism behind how premutation alleles cause disease is not well understood.  
FMRP is expressed at slightly reduced levels; however, there is increased transcription of the 
FMR1 mRNA, suggesting a toxic gain of function [24].   Over-expression of the FMR1 mRNA 
may disrupt proper cellular function due to the expansion of the CGG repeat, causing RNA 
toxicity and the accumulation of intranuclear inclusions in neurons and astrocytes [24, 25].  One 
model is that the accumulation of CGG repeats in the mRNA sequesters proteins away from their 
designated tasks.  Analysis of the protein content of intranuclear inclusions in FXTAS showed 
that hnRNPA2/B1, CUGBP1, and Sam68 were consistently found in these inclusion bodies [26-
29]. Presumably, the paucity of these proteins from their normal sites of activity leads to 
development of either FXTAS or POI.  
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1.3 Features of FXS 
 
 FXS presents with characteristic behavioral and physical features. The incidence of FXS 
is 1 in 4000 males and is about half as frequent in females, who have varying degrees of FXS 
depending on compensatory levels of the unsilenced normal allele.  FXS is characterized by 
developmental delays and intellectual disability.  The average IQ in males is around 40 points 
and in females, around 70 or 80 points due to the X-linked nature of this syndrome.  There is 
high co-morbidity with autism, as FXS is the most common monogenic cause of autism.  
Approximately 25% of fragile X males will qualify as fully autistic while a high majority will 
demonstrate some phenotypes that fall under the ASD umbrella.  Females are less affected, with 
less than 7% with autism [30].  
 It is common for individuals with FXS to have language delays. During normal language 
acquisition, first words are usually uttered around 12 months of age.  Fragile X individuals 
generally utter their first words between the ages of 18 months and 3 years [31].  Males generally 
acquire language later than fragile X females. FXS language deficits also include deficiencies in 
receptive language as well as expressive language.  In studies of conversational skills, fragile X 
individuals took a reduced number of turns and had more difficulty maintaining extended 
communication [32]. Another interesting aspect of language development in FXS is the presence 
of repetitive language.  Individuals demonstrate perseverative language, repeating words that 
have been said to them, as well as echolalia, which is repetition of words spoken by themselves 
[33-35].  
 In addition to their cognitive and behavioral patterns, individuals with fragile X 
syndrome have subtle yet distinct features (reviewed in [36]).  FXS presents with mild 
craniofacial abnormalities and mild connective tissue abnormalities. These individuals are 
difficult to diagnose early in age as the features accumulate over time. Adult males have long 
faces with an enlarged head circumference and prominent forehead and jaw, large ears, as well 
as high arched palate.  After puberty, FXS males develop macroorchidism, or enlarged testicular 
volume, in excess of 25 mL [37]. They also have features of a mild connective tissue disorder, 
which can include velvet-like skin, hyperextensible joints, flat feet and mitral valve prolapse [37-
39]. 
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 FXS dendritic phenotype 
 All of these cognitive and behavioral differences suggest that at a cellular level, there are 
changes in the connectivity of neurons in the brain.  Post mortem samples of FXS brains and also 
from Fmr1 KO mice have shown that there is an excess of long and immature dendritic spines 
compared to age matched normal controls.  Filopodia are the precursor structure to developing 
dendritic spines, suggesting that FXS is a problem of proper dendritic maturation from the 
filopodia to mature spines. Studies done in Drosophila demonstrated that dfmr1 mutants 
developed mushroom body neurons with an excess of branching, which is not usually observed 
in WT flies [40].  Conversely, overexpression of dFMRP resulted in the opposite morphology, 
yielding reduced complexity of dendritic branching and arborization [40].   
 Because FMRP is present in the dendrites, it is not surprising that in its absence, there is a 
neuronal phenotype. FMRP expression itself is dependent on synaptic stimulation [41]. In 
isolated synaptoneurosomes, FMRP was rapidly synthesized in response to metabotropic 
glutamate receptor (mGluR) signaling [42].  As synapse maturation is dependent on protein 
synthesis, FMRP plays an important role in the proper development and maintenance of synapses.  
In addition to the spine phenotype, Fmr1 knockout animals also demonstrate enhanced long term 
depression (LTD) in response to mGluR signaling when compared to wild type animals [43, 44] 
suggesting that FMRP functions as a regulator of translation at the synapse, and is especially 
important for mGluR signaling, which will be discussed in more detail below. FMRP also plays 
a role in regulating actin polymerization and also modulates MAP1B RNA translation in 
response to synaptic stimulation [45-47]. 
 
1.4 FMRP 
 
 FMRP belongs to a small family of RNA binding proteins, consisting of FMRP, FXR1P, 
and FXR2P.  These proteins have about 70% sequence homology and each family member is 
capable of homo- or heterodimerization [48].  FMRP is expressed ubiquitously throughout the 
body, but not in muscle tissue [49].  FMRP has elevated expression in the brain and testes.  In the 
brain, FMRP is highly expressed in cortex and hippocampus as well as abundantly expressed in 
the granule cell layer in the cerebellum [50, 51].  In neurons, FMRP is expressed throughout the 
cell, throughout the cell body and in the dendrites.  FMRP is also present in axons, but at a lower 
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level [52].  Because FMRP contains several RNA binding domains as well as protein interacting 
domains, FMRP can form several messenger ribonucleoprotein particles (mRNPs) and associate 
with a large collection of proteins and RNA, allowing FMRP to take on many different roles as 
both a transport molecule as well as a regulatory molecule.  The exact mechanism behind how 
FMRP specifically regulates its target mRNAs is still unknown and is a question of great interest.  
Some possibilities include binding mRNAs to expose start sites for translation, controlling 
localization, influencing mRNA stability, and also association with the microRNA (miRNA) 
pathway have been suggested and will be described in more detail below.  
 
FMRP RNA binding domains 
 FMRP is an RNA binding protein containing three RNA binding domains consisting of 
two hnRNP K-protein homology domains (KH) as well as an Arg-Gly-Gly (RGG) box [53].  
Currently, no specific RNA substrates have been identified for the KH1 domain while the KH2 
domain binds a complex double stem loop structure called a kissing complex that was identified 
in SELEX experiments [54].  FMRP has been shown to co-immunoprecipitate with components 
of the miRNA pathway, including precursor miRNAs and a number of mature miRNAs [55, 56]. 
While the specific binding target of the KH domains has not yet been completely explored, it is 
of great interest to determine the miRNA binding capabilities of FMRP itself.  The importance of 
the KH2 domain in normal FMRP function was underscored when an individual with extreme 
features of FXS was found to have a single point mutation in the KH2 domain, substituting an 
isoleucine to an asparagine (I304N) [14]. The I304N FMR protein does not associate with 
translating polyribosomes and is deficient in several tests of RNA binding, suggesting gross 
misfolding of the protein as well as inappropriate protein localization and RNA binding [57].  
This mutation describes the necessary role of RNA binding as well as proper localization for 
FMRP to perform its designated tasks. Accordingly, an I304N knockin mouse has features 
similar to the Fmr1 knockout mouse [58]. 
 In addition to the KH domains, FMRP and FXR1P contain an RGG box; however the 
FMRP RGG box has been demonstrated to be unique among the family members because of its 
ability to bind G-quadruplexes with high affinity [59-61].  G-quadruplexes are very stable 
secondary structures found in both RNA and DNA formed by the stacking of guanine (G) tetrads.  
Intramolecular G-quadruplexes in RNA are important regulators of translation that inhibit 
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ribosomal scanning.  The RGG box is the high affinity RNA binding domain of FMRP [7, 60].  
Accordingly, removal of the RGG box disrupts association of FMRP on translating 
polyribosomes, shifting the protein to the free protein fraction and lower polysome fractions [62, 
63].  Further evidence that the association between FMRP and polyribosomes is RNA dependent 
is that FMRP--as well as the other fragile X family members—can be competed off 
polyribosomes by addition of the kissing complex RNAs [54].  The RGG box binds G-
quadruplex structures and has been demonstrated to bind a G-quadruplex containing RNA, sc1, 
with nanomolar affinity; however, similar to the kissing complex RNA, the sc1 sequence per se 
has not been identified in an mRNA and was identified in SELEX experiments [54].  FMRP-
associated mRNAs bear G-quadruplexes in their 5’UTRs, coding sequences and 3’UTRs. A 
number of the mRNAs bound by FMRP have been found to contain G-quadruplexes, such as its 
own mRNA message, FMR1, and other mRNAs such as MAP1b, PSD-95, and semaphorin 3A 
[47, 64, 65].  The interaction between FMRP and some of its target mRNAs has been 
biochemically confirmed to be mediated by G-quadruplexes by several groups [7, 64, 66].  
Another well studied target is the amyloid precursor protein, APP.  APP has a G-rich region 
located within the coding sequence and was also found to be regulated in an mGluR mediated 
manner [67]. A recent study demonstrated that mGluR activation resulted in the release of APP 
mRNA from an FMRP-containing mRNP, resulting in increased translation of APP [68].  FMRP 
binding to G-quadruplexes may help direct mRNAs bearing them to various locations throughout 
a neuron, or even within subcellular granules to facilitate translation or maintain an un-translated 
state of the mRNA.   
 FMRP also binds to uracil (U)-rich tracts along mRNA [46, 69, 70]. In a recently 
characterized mRNA target, the 5’ UTR of human Achaete-scute, FMRP bound the U-rich 
region of the mRNA and also mediated translational upregulation of a reporter construct bearing 
the 5’UTR [70]. How FMRP increases the translation of this reporter is a question of great 
interest as FMRP is largely thought of as a translational repressor, although there is evidence for 
its role as an activator [71].  Another RNA motif that is bound and recognized by FMRP is a 
novel three stem loop structure called SoSLIP that is present in the 5’UTR of the Sod1 mRNA 
[72].  This mRNA forms a three-stem loop structure, SoSLIP, that negatively regulates 
translation until FMRP binds it to open the structure, which exposes the initiator codon of the 
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mRNA, thus increasing expression of Sod1.  The region of FMRP that binds Sod1 has not yet 
been identified; however the C-terminal domain is thought to provide this function [72]. 
 Several lists of FMRP-bound mRNAs have been generated over the years, using a variety 
of techniques to identify the associated mRNAs including microarrays, hybridization to RNA 
arrays, and high throughput sequencing [71, 73]. Over 400 targets have been identified by a 
number of groups, but only a small handful of mRNAs have been studied in depth.  A recent 
paper published by Darnell et al identified FMRP-associated RNAs in brain using High 
throughput Sequencing and Cross-linked Immunoprecipitations (HITS-CLIP).  24% of the RNAs 
were also present in the list generated by Brown and colleagues, while a number of the novel 
RNAs found were involved in the pathogenesis of autism [74].  Interestingly, HITS-CLIP 
revealed that FMRP bound along the length of the mRNA, with a majority of FMRP associated 
with the coding region.  Almost a third of the FMRP bound to RNA was found in the 3’UTR, 
and a small percentage of FMRP was found to be bound to the 5’UTRs.  Given that the targets 
were selected from polyribosomal fractions, it is not surprising that the majority of FMRP is 
found along the coding region.  FMRP was found to play a role in stalling ribosomes.  
 In addition to finding FMRP primarily bound to coding region, this study is also 
remarkable because of the lack of specificity demonstrated by FMRP in its ability to bind 
multiple sites in the coding region of an mRNA.  G-quadruplexes were no more enriched in the 
FMRP-associated mRNAs than in the control immunoprecipitations.  One explanation for this 
observation is that Darnell and colleagues chose to study FMRP-mRNAs isolated from 
polyribosomal fractions in the brains of adult mice instead of choosing from the entire pool of 
FMRP-associated mRNA complexes in the brain.  It is possible that specificity in this fraction 
was limited because FMRP also associates with translating ribosomes, which would correlate 
well with the data showing FMRP enriched along the coding region of RNA.  Significantly, 
FMRP is present in several other cellular components such as the nucleus, and contained within 
stress granules and processing bodies (P-bodies), which were not examined in this study.  
Perhaps the motifs that FMRP would recognize to recruit RNA to other cellular compartments 
would be different than the motifs that would recruit mRNA bound by FMRP to the translational 
machinery.  In fact, FMRP has been shown to bind ribosomes, thus, its RNA binding specificity 
in this compartment might be minimized [75]. For example, because G-quadruplexes are 
translationally inhibitory structures in mRNA, FMRP may potentially bind G-quadruplexes to 
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localize quiescent mRNA to P-bodies for storage in a translationally silent state.  Alternatively, 
FMRP binds some or all of its mRNAs in the nucleus [76]. Perhaps in that compartment, FMRP 
binds mRNAs through specific motifs. Since FMRP can directly bind ribosomes [75], isolating it 
from polysomes reflects a pool of FMRP that is associated with many different mRNAs.  In 
addition, FMRP also plays an important role in neuronal differentiation and development 
throughout embryonic development into adulthood. The use of juvenile mice, as the Darnell 
group did, would also generate a significantly different population of bound mRNA than 
isolating FMRP-mRNA complexes from embryonic or adult animals.   
 
Posttranslational modifications of FMRP 
 
 FMRP is a dynamic protein with many different functions.  FMRP associates with a 
number of proteins and can form a diverse range of mRNA-containing particles.  FMRP is also 
found in many different subcellular compartments such as the nucleus, stress granules, P-bodies, 
and also in various regions of a cell, which is especially significant in highly polarized cells like 
neurons.  Appropriate localization of mRNA targets from the cell body to the dendrite or axon as 
well as activity-dependent translation of mRNAs upon stimulation is important for proper 
development and maintenance of synapses.  Post-translational modifications offer an additional 
mechanism for regulating FMRP function (Table 1). 
 
 Methylation of FMRP 
 The chemical modification of methylation serves two very distinct roles in FMRP 
function and pathogenesis.  DNA methylation is present in the full mutation of FXS, resulting in 
chromatin condensation and silencing of the FMR1 gene [77, 78]. At the protein level, FMRP is 
posttranslationally modified on arginines comprising the RGG box [79, 80].  These arginines are 
mono and asymmetrically dimethylated suggesting that specific protein arginine methyl 
transferases (PRMTs) act on FMRP, namely, PRMT1, PRMT3, PRMT4 and/or PRMT6 based on 
the pattern of methylation and localization in the cell [79]. 
 RGG box arginines 533, 538, 543, and 545 are methylated on murine FMRP in cells, and 
it was demonstrated that arginine methylation reduced the affinity of FMRP for a subset of 
RNAs [63].  In a recent study, the arginine residues were substituted to examine their effect on 
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polysome association and binding to either the model G-quadruplex RNA sc1 or to AATYK, the 
second most common RNA immunoprecipitated with FMRP from brain [71] and that contains a 
putative G-quadruplex.  Blackwell and colleagues found that arginines 533 and 538 were 
required for normal polysome association, suggesting that their substitution led to a disruption in 
RNA binding.  In contrast, association with AATYK did not require arginines at positions 533 
and 538. In addition, methylation of 533 and 538 inhibited binding to sc1 but their methylation 
had no effect on binding to AATYK [63].  These results suggest that differential methylation of 
FMRP can confer binding specificity for different RNA molecules.  To further support the 
importance of these specific residues for RNA binding, a recent study by Phan and colleagues 
examined the binding requirements of the minimal FMRP RGG box to sc1 and obtained an 
NMR structure. Residues 533 and 538 were important for coordinating residues in the sc1 
quadruplex stemloop junction while other arginine residues in the RGG box may be important 
for binding different types of G-quadruplex structures [63, 81].   
 
 Phosphorylation 
 In addition to methylation, FMRP is phosphorylated in cells [82].  A conserved 
phosphorylation site on FMRP is present in both human and Drosophila FMR proteins at serine 
500 and serine 406 respectively [82, 83].  These serine residues act as the primary 
phosphorylation site on FMRP, triggering the phosphorylation of flanking serines [82].  The 
primary phosphorylation site of FMRP is about 30 amino acids N-terminal to the RGG box 
however, phosphorylation of FMRP does not influence RNA binding abilities [82]. Rather, 
phosphorylation seems to act as a switch between actively translating polyribosomes and stalled 
untranslating polyribosomes, suggesting that phosphorylation regulates the step of elongation 
where removal of the phosphate group signals to resume translation. In studies using point 
mutations of FMRP such that it mimics constitutively phosphorylated FMRP and 
unphosphorylated FMRP, it was found that phosphorylated FMRP was more resistant to 
ribosomal runoff than unphosphorylated FMRP suggesting that unphosphorylated FMRP is 
associated with actively translated polyribosomes [74, 82]. Phosphorylated FMRP was studied 
using the constitutively phosphorylated and dephosphorylated serine mutants, S500A and S500D 
respectively [84].  While the presence of constitutively phosphorylated FMRP had no effect on 
synapse strength or function, dephosphorylated FMRP showed a decrease in synapse strength as 
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well as a reduction in synapse number suggesting that WT FMRP exists in a dephosphorylated 
state in hippocampal slice cultures and was important as a post synaptic regulator at the synapse 
[84]. To evaluate the role of phosphorylation in vivo, Coffee and colleagues substituted human 
FMRP into an Fmr1 knockout strain in Drosophila to evaluate protein function.  Interestingly, 
S500D was found to restore the protein levels as well as neural architecture at the neuromuscular 
junction while S500A did not [85]. Phosphomimic FMRP also rescued associative learning 
performance in Drosophila [85].  Based on these studies, postsynaptic FMRP is important for 
proper synaptic pruning and normal function.  In recent studies using HITS-CLIP, it was found 
that FMRP bound along coding region of mRNA transcripts.  This suggests that somehow, 
FMRP associated with ribosomes can consistently be found stalled and associated with coding 
regions within mRNA.   
 What then, are the implications of FMRP phosphorylation on mRNA targets? In 
hippocampal neurons, it was found that ribosomal protein S6 kinase (S6K1) is a major kinase of 
FMRP while PP2A is the major phosphatase [86, 87]. FMRP is phosphorylated and de-
phosphorylated in an activity dependent manner. FMRP is rapidly dephosphorylated 
immediately after group1 mGluR stimulation by DHPG but is then rapidly re-phosphorylated 
within minutes of stimulation.  One well-studied example of a dendritically localized mRNA 
regulated by FMRP is SAP90/PSD-95-associated protein 3 (SAPAP3).  Loss of S6K1 resulted in 
an overall increase in FMRP target SAPAP3.  Cells expressing the alanine substituted FMRP 
showed a similar increase in SAPAP3, while mRNA levels remained constant [86].  Thus, by an 
unknown mechanism, phosphorylation acts as in inhibitor of translation.      
 FMRP localized to the synapse plays an important role in the regulation of translation, 
and phosphorylation may play a pivotal role in managing the balance of translated and repressed 
mRNAs.  Upon mGluR stimulation of the synapse, FMRP is rapidly synthesized.  Additionally, 
FMRP that is already localized to the synapse is rapidly dephosphorylated, resulting in a burst of 
translation. Minutes after stimulation, FMRP is then rapidly phosphorylated.  Protein translation-
dependent synaptic strengthening such as LTP and mGluR LTD is perturbed in fragile X 
knockout mice.  Perhaps the presence of the FMRP complex at the synapse is poised to rapidly 
regulate translation of its associated mRNAs upon the appropriate signal.  
 
 
12 
 
 Phosphorylation of FMRP, and miRNAs at the synapse 
 Post-synaptic density protein 95 (PSD-95) is a prime example of how translation of an 
FMRP-associated mRNA is regulated by post-translational modifications at the synapse.  The 
3’untranslated region of PSD-95 contains a miR-125a binding site that is buried within a G-
quadruplex region that is bound and recognized by FMRP [88].  PSD-95 expression is mGluR 
stimulation-dependent, such that treatment with DHPG results in an increase of translation.  
Binding of miR-125a to PSD-95 inhibits translation, while mutating the seed sequence lifted 
miRNA-mediated inhibition of the mRNA. Using mutants of FMRP that mimic constitutively 
phosphorylated or unphosphorylated FMRP, it was found that constitutively phosphorylated 
FMRP inhibited PSD-95 translation while unphosphorylated FMRP was a permissive signal for 
translation.  In addition to translational suppression by FMRP, Argonaute 2 association with 
PSD-95 mRNA was increased in the presence of phosphorylated FMRP.  The model proposed 
by Muddashetty and colleagues is that phosphorylated FMRP associates with Argonaute 2 and 
the RISC machinery in a suppressive state on PSD-95.  However upon mGluR stimulation with 
DHPG, FMRP is rapidly de-phosphorylated, causing the RISC machinery to dissociate from the 
mRNA, liberating PSD-95 from the suppressed state to an actively translating state [56].  
Because phosphorylation is reversible, soon after stimulation, FMRP may be rephosphorylated, 
thereby returning PSD-95 mRNA to a translationally silent state once again.  Thus, 
phosphorylation of FMRP works as a reversible switch to permit or inhibit translation of PSD-95. 
 While FMRP associates with RISC machinery on an mRNA, FMRP also associates with 
other components of the miRNA machinery.  Phosphorylation inhibited association of Dicer with 
FMRP, leading to accumulation of an RNA the size of a precursor microRNAs. This observation 
suggests that phosphorylation of FMRP may regulate association with Dicer and consequently 
processing of pre-miRNAs to miRNAs [89]. 
 
 Ubiquitination 
 In addition to methylation and phosphorylation, FMRP is also ubiquitinated.  In neurons, 
LTP and LTD both require the synthesis of specific proteins to maintain the longevity of the 
response.  The ubiquitin-proteasome pathway is important for cellular degradation of proteins.  
Expression of FMRP increases in the soma and proximal dendrites after DHPG stimulation, with 
a notable increase of nuclear FMRP [90]. The presence of nuclear FMRP is interesting especially 
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after a burst of FMRP synthesis.  Newly synthesized FMRP maybe triggered to enter the nucleus 
and bind target mRNA before targeting it to specific destinations.  After an initial burst of FMRP 
expression, the levels of FMRP returned to a basal state after 10 minutes which suggested a 
mechanism by which FMRP protein levels were rapidly modulated [90].  FMRP was found to be 
degraded by the 26S proteasome, where blocking proteasomal activity with MG132 resulted in 
sustained levels of FMRP after DHPG stimulation.  Blocking degradation of FMRP resulted in 
the inhibition of mGluR mediated LTD, which is consistent with the exaggerated LTD in Fmr1 
knockout mice.  Thus, ubiquitin serves as a mechanism to modulate the steady-state levels of 
FMRP at the synapse.   
 
1.5 FMRP and the fate of progenitor cells 
 
 Neurogenesis is a complex series of events that takes place throughout life.  Striking the 
proper balance between forming neurons versus supporting glial cells and then forming cells that 
can be integrated into a functional circuit is a challenging task that the brain must perform [91]. 
Developmentally, FMRP plays an important role in dictating the fate of precursor cells in the 
developing brain.  FMRP also plays a role in the regulation of cell cycle and neural progenitor 
proliferation [92]. A recent review by Callan and Zarnescu elegantly summarizes the effects of 
FMRP on progenitor cells and neurogenesis [93]. The loss of FMRP altered the ratio of neurons 
to glia in both embryonic and developing cells and also even in adult tissues [94]. Loss of FMRP 
in embryonic cells resulted in increased development of neurons with a decrease in glia.  This 
was found to be due to reduced viability of glial cells which would suggest that in early 
development, FMRP plays an important role in the maintenance of glia [94].  Interestingly, the 
role of FMRP in progenitor cell differentiation takes on a reverse role in adult cells.  
Developmental timing of differentiation as well as the different mRNA targets during neuronal 
development may skew progenitor differentiation to favor glial development in developmentally 
older animals [92].  Comparison of WT to Fmr1 knockout mice showed that knockout mice had 
decreased levels of neurogenesis with an increase in astrocytes, predominantly in the adult 
hippocampus of mice.   
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1.6 FMRP localization in cells 
 
 FMRP is present throughout the neuron, and with the number of posttranslational 
modifications that are present on FMRP, cellular localization also adds another element of 
translational control and regulation of bound mRNAs (Figure 1).  
 
 Nuclear FMRP 
 At a cellular level, FMRP is generally cytoplasmic, however, a small amount of FMRP 
has been described in the nucleus at steady state. Early stages of Xenopus and zebrafish 
development, 2 and 3 hours post fertilization, respectively, have shown that FMRP is primarily 
nuclear, suggesting an important role for FMRP in the nucleus during specific points in 
development [95, 96].  Further, FMRP has been found along nascent transcripts in the lampbrush 
chromosomes of Xenopus laevis oocytes suggesting that FMRP enters the nucleus to bind its 
nascent mRNA targets before being exported to the cytoplasm and properly localized for 
translational regulation [76]. Exactly how FMRP finds its mRNA target while in the nucleus is 
still not yet clear, but it can be speculated that specific RNA motifs such as RNA G-
quadruplexes and arginine methylation of FMRP may help to guide and facilitate RNA binding. 
Upon stimulation by DHPG, the localization of FMRP in the hippocampus was found to be 
increased in the nucleus and also throughout the dendritic arbor suggesting rapid transport into 
the nucleus to bind mRNA cargo and also rapid synthesis in response to stimulation at the site of 
regulation [90]. 
 Immunogold labeling showed FMRP in the nucleoplasm and associated with the nuclear 
pores of neurons but not in astrocytes or glia [97].  FMRP has a non-canonical nuclear 
localization sequence encoded by exons 5, 6, and part of 7 that contains lysines and arginines but 
does not contain a canonical importin alpha binding sequence [98, 99].  Thus, it is unclear how 
FMRP enters the nucleus.  In addition to its RNA binding domains, FMRP has a leucine-rich 
nuclear export sequence (NES) encoded by exon 14 that is alternatively spliced.  Accordingly, a 
splice variant of FMRP lacking exon 14 was found to be primarily nuclear in localization.  The 
leucine-rich NES in FMRP is similar to the Rev regulatory protein of HIV1 and was proposed to 
bind CRM1 [100].  However, FMRP has additional mechanisms for exiting the nucleus.  
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Blocking the primary mRNA exporter, Tap/Nxf1, increased the nuclear localization of FMRP 
suggesting that the export of FMRP is mediated by its bound mRNA [76].   
 
FMRP association with the translation machinery 
 FMRP associates with mRNAs bound to multiple ribosomes, termed polyribosomes, in 
the cell body and in synaptoneurosomes suggesting a role in translation regulation at the synapse 
[41, 97, 101].  Despite the extensive studies done to understand FMRP and its effects on 
translation, a clear mechanism behind how FMRP regulates translation of its bound mRNAs has 
yet to be elucidated.  One model of FMRP mediated translation regulation begins at the step of 
translation initiation.  Translation begins by assembling a number of proteins at the 5’methyl 
guanosine cap including eIF4E and eIF4G, which assemble into the translationally competent 
eIF4F complex.    Formation of this complex is inhibited by 4F binding proteins, 4FBP.  FMRP 
may act as an inhibitor of initiation through its association with CYFIP, which was recently 
described as a 4FBP [102]. CYFIP has been shown to contain no RNA binding ability, therefore 
its localization and function in an mRNP would be mediated by protein-protein interactions. 
CYFIP interacts with a region encoded by exon 7 in FMRP which is also the region of 
interaction between FMRP and its family members, FXR1P and FXR2P [103].  The ability of all 
of these proteins to bind the same domain in FMRP suggests a complex form of regulation where 
association with CYFIP may inhibit translation while association with other proteins such as the 
fragile X family members may activate translation. 
 In addition to translational machinery, FMRP is found associated with many RISC 
proteins in both Drosophila and mammals.  As mediators of translational suppression, it comes 
as no surprise that FMRP would be closely associated with RISC proteins.  While FMRP does 
not seem to be necessary for proper function of the RISC machinery [104], it seems evident that 
FMRP can serve as a vehicle to localize mRNA to the RISC machinery.  FMRP associates with a 
number of neuron specific miRNAs.  A recent paper by Edbauer and colleagues described FMRP 
and its role in modulating the effect of mi-125b and miR-132 where miR-125b overexpression 
resulted in more immature dendritic phenotypes [55]. Not only was FMRP found to be 
associated with miRNAs, a novel target, the NMDA receptor subunit, NR2A was also found to 
be regulated by miR-125b in an FMRP-dependent manner [55].   The specific mechanism behind 
how FMRP can guide miRNAs to target mRNAs is still unknown. 
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FMRP in translationally silent granules 
 Subcellular RNA containing granules called processing bodies (P-bodies) and stress 
granules (SG) are present throughout the cytoplasm, harboring mRNA molecules sequestered 
from translationally active machinery (reviewed in [105]).  These two translationally silent 
compartments are very similar and contain many regulatory molecules however their presence is 
dependent on cellular conditions such as the translational state of the cell as well as the presence 
of various stressors such as oxidative stress. 
 P-bodies are another subcellular compartment where non-translated mRNA is kept for 
transient storage or degradation [106-108].  Several proteins associated with nonsense-mediated 
decay such as Dcp1 and Upf1 are present in P-bodies in addition to components of the RISC 
machinery [109, 110].  mRNAs targeted for degradation or sequestration may be localized to P-
bodies for storage by FMRP until a signal for translation activation is triggered.  Upon exiting 
the P-bodies, the mRNA is then actively translated [110, 111].   APP, a known binding target of 
FMRP is recruited to P-bodies to silence translation in competition with hnRNP C [68]. By this 
mechanism, FMRP may physically sequester a bound mRNA to cellular compartments that are 
not regions of active translation.   
 Cellular stress triggers a complex response from the cell such that translation is rapidly 
reduced as a means for the cell to survive the duration of the stressor.  Triggers such as oxidative 
stress, UV irradiation, heat shock, and other extreme conditions result in the organization and 
accumulation of stress granules in the cytoplasm [112-115].  FMRP localizes to stress granules 
where it is thought to bind quiescent transcripts that are targeted for degradation or storage.  
Interestingly, formation of stress granules results in a shift of mRNA away from the translational 
machinery into aggregates of protein that also contain a double stranded RNA binding protein, 
Staufen, which is thought to facilitate ribosome stalling [116].  FMRP, which associates with 
stalled nontranslating polyribosomes in a phosphorylated state, also associates with Trdr3 and 
Staufen which may suggest that these two proteins coordinate a stress granule assembly response 
[117].  In cells lacking FMRP, it was found that stress granule assembly was altered while RISC 
activity remained intact suggesting that FMRP is a component of stress granule assembly [104]. 
The association of FMRP with these stress granule and P-body components greatly underscores 
the important role of FMRP in mRNA regulation.  
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FMRP and mRNA transport 
 Important for translational regulation is the proper localization of mRNAs to cellular 
targets.  This targeting mechanism is especially important in highly polarized cells such as 
neurons. FMRP associates with a number of molecular motors such as dynein and kinesins, with 
mammalian FMRP associating with neuron-specific kinesin, KIF3C, and mRNA targets such as 
CamKII and Arc/arg [118, 119].  Interestingly, the RNA transport granules that contain FMRP 
also contain RNA helicases, Poly-A binding proteins, splicing factors and nuclear/cytoplasmic 
shuttling factors.  Upon mGluR stimulation, FMRP and RNA-containing granules demonstrate 
bi-directional movement suggesting that FMRP may play a role as a localization protein such 
that bound mRNA can be translated at the site of stimulation [120].   In studies using neuron 
culture, CamKII alpha was used as a regulated cargo.  After mGluR stimulation, FMRP was 
found to be rapidly colocalized to spines containing group 1 mGluRs within 20 minutes [120]. 
Additionally, FMRP targeted CamKII alpha to the spines for rapid translation.  In studies done 
using dFMR1, the motility, speed, and distance of specific FMRP target mRNA granules was 
altered after DHPG stimulation. FMRP also affects cellular localization of some, but not all 
target mRNAs [73, 121].  In the absence of FMRP, some mRNAs are mislocalized and absent 
from synapses perhaps due to a lack of transport from the soma to respective cellular 
compartments. 
 A small amount of FMRP has also been found in axons along developing growth cones, 
suggesting an important role in regulating the translation of mRNAs in the axons, which is 
especially important in developing proper neural circuitry during development [122].  Expression 
of dFMRP mutants demonstrated more complex branching of axons, appearing to encroach on 
inappropriate brain areas [40].  dFMRP in the mushroom bodies of Drosophila was found to 
regulate the complexity of axonal branching during development.  Activity-dependent pruning of 
axons is an important role of dFMRP in the developing mushroom body [123]. On a molecular 
level, FMRP and mRNA containing granules were located in the axonal growth cones, and out in 
the axonal filopodia with Map1b mRNA [124-126]. Proper development of neural circuitry 
requires the appropriate localization of mRNAs that are capable of responding to external 
stimulation such as growth cone regulation and translational regulation in response to signals 
such as netrin-1 and Sema3a [127]. FMRP in the axon is proposed to play an important role in 
managing protein synthesis and localization in the growth cone [52]. 
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 FMRP at the synapse 
 Synaptic activity can create changes in the stability of synapses, such that they can be 
strengthened in the case of LTP, allowing new connections to be maintained.  Conversely, LTD 
can result in the destabilization and elimination of synapses.  These long-term responses require 
the activation of post-synaptic protein translation of mRNAs already present in the synapse in 
response to group 1 mGluRs, which include mGluR1 and mGluR5 [44].  Several interesting 
observations were made by Huber and colleagues where the absence of FMRP somehow resulted 
in exaggerated LTD in neurons which ultimately resulted in the development of the mGluR 
theory [43].  Dysregulated signaling through over-active group 1 mGluRs results in many 
characteristic features such as developmental delay and long thin spines, which are also distinct 
characteristics of fragile X syndrome. Since then, the interaction between FMRP and the 
response to metabotropic glutamate receptor stimulation has sparked an immense interest in the 
role of FMRP at the level of the synapse.  
 
1.7 mGluR theory of FXS 
 The connection between FMRP and the group 1 mGluRs has been of great interest, 
leading to many new ideas regarding the role of FMRP and translation at the synapse. Proteins 
that are thought to stabilize LTD are synthesized in the synapse in response to mGluR 
stimulation, and along with this milieu of proteins, FMRP is also coordinately synthesized [41, 
44, 128].  Activation of mGluR5 triggers a cascade of signaling molecules along the MAPK and 
ERK pathways.  mRNAs already present at the synapse are rapidly translated, resulting in a burst 
of protein synthesis upon group 1 mGluR stimulation [65, 129]. Along with this burst of 
translation, after prolonged stimulation, surface AMPA receptors are rapidly internalized [130].   
The mGluR theory proposes that FMRP acts as a brake, to inhibit further synthesis of LTD 
proteins. Therefore Fmr1 knockout mice have continuously dysregulated synthesis of LTD 
proteins.  Because of this exaggerated mGluR signaling, synaptogenesis is perturbed, especially 
during critical periods of development. 
 
1.8 Current therapies for FXS 
 Understanding the role of FMRP at the synapse has led to several therapeutic avenues in 
an attempt to tackle the dysregulated signaling in FXS (Figure 2).  Several therapeutic agents 
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have been developed to ameliorate the downstream effects in patients with FXS.  While it would 
seem that targeting downstream signaling would be an ideal method to treat FXS, the effects of 
perturbing universal signaling cascades must also be taken into consideration.  One such example 
would be to target the MAPK/mTOR/ERK cascade with the use of general inhibitors.  While this 
approach would address the dysregulated signaling in neurons, this signaling cascade is involved 
in many other cellular processes such as cell cycle regulation.   
 Negative modulators or antagonists of mGluRs are a promising target for managing FXS, 
as exaggerated mGluR signaling is a major proposed mechanism of disease phenotype [43, 131].  
MPEP (2-methyl-6-phenylethynyl pyridine hydrochloride) is a strong negative regulator of 
mGluR5 receptors [132].  In mice and Drosophila, MPEP significantly improved behavior and 
reversed the fragile X phenotype, showing marked improvement in courting behavior in 
Drosophila and reduced hyperactivity and audiogenic seizure induction in mice [133-135]. 
Additionally, at the cellular level, AMPA receptor internalization was also reduced [136]. While 
this molecule was promising in animals, the use of MPEP in humans was too toxic [137].  A 
different specific blocker of mGluR5 was used in clinical trials called fenobam.  Single treatment 
of fenobam showed marked reduction in hyperactive behaviors and anxiety, however longer term 
studies were not performed [138].  Other mGluR5 modulators and antagonists that are in clinical 
trials are AFQ056 (Novartis) and RO4917523 (Hoffman La Roche),which have progressed into 
Phase II of clinical trials (clinicaltrials.gov).  
 One aspect of FXS is the excessive internalization of AMPA receptors from the cell 
surface [130, 136]. Targeting AMPA internalization by using AMPA receptor modulators 
(ampakines) is another potential avenue for therapy. Ampakines essentially trigger BDNF 
signaling and stimulate mRNA translation such that LTD is facilitated [139]. CX516 is a weak 
ampakine that was used in a few clinical trials, however there were few significant 
improvements in cognitive and behavior results [140] . 
 Lithium has been used to treat neurological disorders for several years, and in a recent 
study, it was found that lithium treatment in Fmr1 knockout mice improved hyperactive and 
social behaviors [141]. In cells, lithium inhibited excessive protein synthesis by blocking inositol 
phosphate signaling pathways [142, 143]. In human clinical trials, there were minimal major side 
effects and some improved behaviors on the irritability and adaptive behavior scales [143].  
Interestingly, lithium treatment also showed that ERK1/2 phosphorylation, which is overactive in 
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FXS, in the lymphocytes of the human subjects were reduced [144]. These studies are still 
incomplete and pose a promising avenue for FXS therapy, however the long term effects of 
systemic lithium treatment are a concern.  Developing a more targeted and effective method to 
administer and regulate lithium is an area that requires more study. 
 Minocycline, in addition to being used to treat acne and other bacterial infections, has 
been used in clinical trials as a target of a specific dysregulated downstream, matrix 
metalloprotease 9, MMP9.  Minocycline is a tetracycline analog that has been used as a 
therapeutic agent in several other neurodegenerative disorders such as multiple sclerosis, autism 
and stroke [145].  Studies using Fmr1 knockout mice showed that minocycline treatment 
improved the behavioral phenotype and also showed changes in the immature dendritic 
phenotype to a more mature phenotype [145].  In human clinical trials, 20 individuals given 
minocycline demonstrated improved behavior without major side effects [146]. Other studies 
showed marked improvements in behavior, language, and attention [147]. While this study still 
requires more investigation, it is a promising therapeutic agent that has already been 
demonstrated to be useful for other health purposes. One concern, however, was the timing of 
administration.  There was a high risk of yellowing or browning of permanent teeth in children 
who were given minocycline before the age of 12, therefore finding an optimal window for 
treatment is a necessary study [148].   
 Arbaclofen is another molecule that has been considered for FXS therapy.  Arbaclofen is 
the right-handed enantiomer of baclofen, and is a potent GABA b agonist (reviewed in [137]).  
As a GABAergic agonist, it has been used in patients who have spasticity due to stroke and also 
in children with cerebral palsy (reviewed in [149, 150]).  The GABA system in Fmr1 knockout 
mice is dysregulated, showing downregulation in activity, therefore using this drug for human 
trials seemed promising.  Arbaclofen indirectly modulates mGluR signaling by lowering 
glutamate that is available at the synapse [137].  Clinical trials showed improvements in 
aggression and irritability, and further testing is still necessary.   
 Several other small molecules are being used in clinical trials, many of which have a 
broad range of effects along many points leading to dysregulated signaling.  In the future, 
perhaps a combinatorial drug treatment will be useful or development of more specific and 
targeted drug therapies.  
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1.9 MOV10 
 
 MOV10 was identified in an insertional mutation study of the Moloney leukemia virus 
(MOV). Insertion number 10 was then identified to be within a gene encoding a 110 kDA 
putative GTP binding protein/RNA helicase [151, 152].  Introductory studies showed that there 
was developmental control of expression, and that MOV10 was expressed in a number of tissues, 
including the brain and testes [152].   In the early 2000s, MOV10 re-emerged as a protein of 
interest as small RNAs caught the eye of the scientific community.  MOV10 was 
bioinformatically determined to be a homolog of SDE3, a superfamily 1 RNA helicase required 
for gene silencing in Arabidopsis [153].  SDE3 and MOV10 displayed similar helicase domain 
homology to UPF1 and SMG-2, which are required for nonsense mediated decay (NMD) in 
yeast and C. elegans.  
 To this day, MOV10 remains largely uncharacterized.  It has been found to have 
sequence homology to other superfamily 1 helicases such as UPF1 [154].  SDE3 in Arabidopsis, 
armitage in Drosophila, and also sequence homology to the MOV10 like protein, specific to 
cardiac muscle [153-155].  However, despite the little that is known about the enzymatic 
function of MOV10 itself, the protein has been published to participate in a number of important 
cellular functions such as the miRNA pathway.  MOV10 plays an important role in RNA virus 
replication and infectivity and has also been found to be involved in the miRNA pathway, which 
will be discussed in the sections below. 
 
 MOV10 and RNA viruses 
 Hepatitis D virus and HIV are both retroviral viruses that require the assistance of host 
proteins to replicate their genetic material and also package and secrete more virus particles.  
Hepatitis D virus is the smallest known virus, encoding a single protein, the hepatitis delta 
antigen.  Knockdown of MOV10 inhibited replication of the HDV genome [156].  A proposed 
mechanism by which MOV10 is thought to influence genome replication is through modification 
of viral RNA of HDV which mimic small RNA hairpins to form a transcriptionally competent 
RNP [156].   
 In 2010, several labs demonstrated that increased expression of MOV10 inhibited HIV 
replication and infectivity [157-159]. In the case of HIV, MOV10 plays a complex role in HIV 
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genome replication and also virus infectivity. The exact mechanism by which MOV10 inhibits 
HIV is still under investigation.   MOV10 significantly reduced HIV infectivity compared to 
other RISC protein components such as Ago1 and 2 and TRBP [157].  In studies of P-body 
related proteins, MOV10 but not DCP1 or 2 inhibited HIV replication.  Interestingly, MOV10 
was also packaged with the virus particles and subsequently impaired virus infectivity [158].  A 
point mutation in the helicase domains of MOV10 showed that HIV infectivity was not affected 
suggesting an important role in the N terminal region of the protein [159].  In a similar study, 
however, all domains of MOV10 except for domain V, typically involved in ATP hydrolysis 
[160] were found to be required for HIV packaging function [161].  The various roles of MOV10 
in RNA virus biology suggest a complex function for MOV10— ranging from secondary 
structure binding to facilitating protein interactions.  
 
MOV10 in the miRNA pathway 
 With 30-40% sequence homology to SDE3 in Arabidopsis thaliana and armitage in 
Drosophila melanogaster, MOV10 is implicated in small RNA processes based on conservation 
of function. Armitage is required for RISC maturation by facilitating siRNA incorporation into 
the complex [155].  In 2005, Meister et al. purified Ago1 and 2 containing complexes to 
determine what protein components were present.  In addition to Gemin 3 and 4 and Dicer, 
TNRC6B, MOV10, and PRMT5 were found in the Ago2 containing complex [162].   MOV10 
and Ago2 co-localize in cytoplasmic granules, which stained positively for P-body markers.  
Isolated complexes of MOV10 demonstrated no Dicer activity suggesting that MOV10 acts 
downstream of Dicer processing and only transiently associates with RISC assembly. MOV10 
was required for miRNA mediated mRNA cleavage. Knockdown of MOV10 relieved miRNA 
mediated silencing of reporter constructs in studies using miR21 and let-7b [162, 163].   
 In other studies of RISC protein components, TRBP containing complexes generally exist 
in a 500 kDa complex, however larger complexes in the 2 mDa range also exist [163].  This 
mega-dalton sized complex was found to contain large subunit components of the ribosome, eIF6, 
and also MOV10.  While the association of these proteins were not as robust as the core RISC 
components, Ago2 and Dicer, miRNA mediated silencing of let-7b targeted luciferase reporters 
were impaired when eIF6 and MOV10 were knocked down [163].   
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MOV10 at the synapse 
 Translation at the synapse is important for plasticity, learning and memory.  MOV10 is 
expressed in a number of tissue types, including the brain.  Banerjee et al. showed MOV10 
present at the synapse in neurons.  Interestingly, KCl stimulation, which activates NMDA 
receptors resulted in rapid degradation of MOV10 containing granules.  Furthermore, this 
degradation was proteasome and activity dependent.  mRNAs known to be associated with RISC, 
namely CamKII and LimK1, were found to be actively translated upon stimulation.  LimK1 is a 
target of brain enriched microRNA, miR138, suggesting that MOV10 degradation relieved 
translational silencing through the RISC complex [164].   
 These studies have sparked great interest in the role of MOV10 in translation regulation, 
however very little is known about how MOV10 functions in the cell, and the specific role in 
regulation that the protein performs.    
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1.10 Figures and Tables. 
 
Figure 1.1. Cellular localization of FMRP.  A.  FMRP enters the nucleus and binds nascent 
mRNA transcripts, which facilitate its export from the nucleus to the cytoplasm. B.  
Translationally silent FMRP-containing granules that harbor mRNA in P-body or Stress Granule 
type compartments.  C.  FMRP can associate with translationally competent mRNA, found along 
actively translating polyribosomes.  D.  FMRP associates with motor proteins to localize mRNAs 
to the dendrite or E. localize mRNAs to the axon to regulate translation of bound mRNA.  F.  In 
response to mGluR stimulation, postsynaptic FMRP is rapidly dephoshorylated and subsequently 
rephosphorylated such that regulation of protein synthesis is tightly regulated. 
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Figure 1.2. Drug targets at the Fragile X synapse. Loss of FMRP affects many different aspects 
of proper synaptic function from protein synthesis to proper downstream signaling and also 
receptor endocytosis.  Several drug candidates have been used in drug trials and animal models 
including mGluR antagonists such as MPEP, Fenobam, AFQ056, RO4917523.  Other targets are 
AMPA receptor agonists through the actions of ampakines, GABAb B agonists present on both 
the pre and post synaptic terminals to regulate glutamate availability at the synapse.  Other small 
molecules such as Lithium and minocycline act to regulate signaling cascades and protein 
translation targets.   
  
26 
 
Table 1.1.  Modifications of FMRP and effects on translation 
Modification Effect on FMRP Effect on Translation Reference 
Phosphorylation 
P-FMRP associates with stalled 
untranslating polyribosomes, 
P-FMRP does not associate with 
Dicer 
P-FMRP associates with RISC 
Inhibits translation 51, 85, 86 
Methylation Alters mRNA binding specificity Unknown 59, 68, 78 
Ubiquitnation 
Triggers FMRP for degradation at 
the synapse 
Increases translation 87 
Splicing 
Changes exon composition of 
FMRP 
Alters FMRP 
localization 
97 
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Chapter 2. FMRP binds mRNAs in the nucleus  
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2.1 Abstract 
 The fragile X mental retardation protein FMRP is an RNA binding protein that associates 
with a large collection of mRNAs. Since FMRP was previously shown to be a nucleocytoplasmic 
shuttling protein, we examined the hypothesis that FMRP binds its cargo mRNAs in the nucleus. 
The enhanced green fluorescent protein-tagged FMRP construct (EGFP-FMRP) expressed in 
Cos-7 cells was efficiently exported from the nucleus in the absence of its nuclear export 
sequence and in the presence of a strong nuclear localization sequence (the simian virus 40 
[SV40] NLS), suggesting an efficient mechanism for nuclear export. We hypothesized that 
nuclear FMRP exits the nucleus through its bound mRNAs. Using silencing RNAs to the bulk 
mRNA exporter Tap/NXF1, we observed a significantly increased number of cells containing 
EGFP-FMRP in the nucleus, which was further augmented by removal of FMRP's nuclear export 
sequence. Nuclear-retained SV40-FMRP could be released upon treatment with RNase. Further, 
Tap/NXF1 coimmunoprecipitated with EGFP-FMRP in an RNA-dependent manner and 
contained the FMR1 mRNA. To determine whether FMRP binds pre-mRNAs cotranscriptionally, 
we expressed hemagglutinin-SV40 FMRP in amphibian oocytes and found it, as well as 
endogenous Xenopus FMRP, on the active transcription units of lampbrush chromosomes. 
Collectively, our data provide the first lines of evidence that FMRP binds mRNA in the nucleus. 
 
2.2 Introduction 
 Fragile X syndrome is one of the most common forms of inherited mental retardation, 
affecting approximately 1/4,000 males and 1/8,000 females (reviewed in reference 34). Fragile X 
syndrome is caused by the loss of expression of the fragile X mental retardation protein FMRP 
(32, 40, 64, 77, 84), which is a highly conserved RNA binding protein with two KH domains and 
an RGG box (6, 70, 71). The N terminus (2, 86), KH1 domain (1), KH2 domain (17), and the 
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RGG box (12, 18, 69) have all been reported to bind RNA. FMRP is estimated to associate with 
approximately 4% of brain mRNAs (6, 12), and two large collections of associated mRNAs have 
been described (12, 58). 
 FMRP is primarily cytoplasmic by both immunostaining and biochemical fractionation 
(22, 30); however, it contains a functional, nonclassical nuclear localization sequence (NLS) near 
its N terminus (7, 24, 73). Immunogold studies have shown that FMRP is present in the neuronal 
nucleoplasm and within nuclear pores (30). In addition, the presence of FMRP in the nucleus is 
regulated temporally, such that at specific times during development, FMRP is predominantly 
nuclear. Studies in Xenopus tropicalis embryos showed that FMRP was largely nuclear 2 h 
postfertilization (stage 6), suggesting a special nuclear function during this developmental period 
(9). Zebrafish embryos also demonstrated predominantly nuclear FMRP staining very early in 
development, 3 h postfertilization (81). Interestingly, these time points coincide with times in 
development when no zygotic transcription is taking place (62), providing indirect evidence that 
FMRP export from the nucleus might depend on mRNA synthesis. 
 FMRP has been speculated to enter the nucleus to bind its mRNAs (25, 46, 78), although 
there is no evidence to support this assertion other than the fact that FMRP has an NLS and is 
occasionally nuclear. Some RNA binding proteins do enter the nucleus to associate with their 
mRNA cargoes and facilitate export to the cytoplasm, for example, the zipcode binding protein 
ZBP1 (43), hnRNP A2 (reviewed in reference 28), and Drosophila proteins Sqd (35, 38) and 
Y14/Tsunagi (37, 50, 53). 
 The nuclear protein Tap/NXF1 was originally characterized as the exporter of retroviral 
RNAs bearing the constitutive transport element (CTE) (11, 36, 49). Since then, Tap/NXF1 has 
been identified as the primary exporter of cellular mRNAs (reviewed in references 15, 44, 56, 61, 
and 80) by binding mRNAs directly through CTE-like elements (10, 55) or indirectly through 
association with other RNA binding proteins. Tap/NXF1 has been demonstrated to interact with 
proteins bound to the mature mRNA like the SR proteins (41, 42) and proteins in the exon 
junction complex, like Aly/Ref (68), supporting the idea that mRNA export is tightly coupled to 
splicing (reviewed in references 46 and 47). 
 To begin to understand how FMRP identifies and binds its collection of mRNAs, it was 
critical to establish where mRNA binding occurs. We hypothesized that this association takes 
place in the nucleus. We show here that FMRP functionally interacts with the bulk mRNA 
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exporter Tap/NXF1, suggesting that these proteins associate through mRNAs bound in the 
nucleus. Further, we demonstrate that FMRP associates with the active transcription units of the 
lampbrush chromosomes (LBCs) in amphibian oocytes. Taken together, we provide the first 
direct evidence that FMRP binds mRNAs in the nucleus. 
 
2.3 Results 
FMRP requires an efficient nuclear export mechanism in addition to its NES. 
 In order to test whether FMRP binds its cargo mRNAs in the nucleus, we strove to 
develop an experimental system in which a significant amount of FMRP would be nuclear. We 
used an EGFP-FMRP construct, described previously (75), for the direct visualization of FMRP 
cellular trafficking. Importantly, it was previously shown that EGFP-FMRP has RNA binding 
properties and transport characteristics indistinguishable from the native protein (3, 19, 21, 75). 
EGFP-FMRP was found to localize primarily within the cytoplasm of transfected cells (Fig. 1A), 
as described before (22), while only ~0.4% of the cells displayed predominantly nuclear EGFP-
FMRP (Fig. 1F). 
 FMRP has an NES encoded within exon 14 that was defined by deletion analysis: its 
removal increased the localization of FMRP ΔNES (hereafter referred to as ΔNES) to the 
nucleus (5, 24, 73). The NES of FMRP is similar to the Rev/protein kinase A inhibitor-type NES 
and can even function in place of the Rev NES in an export assay (31). Further, treatment with 
leptomycin B, which blocks the nuclear export of proteins containing leucine-rich NESs by 
inhibiting interaction with CRM1/exportin 1 (33, 65, 74), resulted in some nuclear accumulation 
of FMRP (78). Accordingly, we found that the removal of the NES from EGFP-FMRP resulted 
in an increased nuclear accumulation of ΔNES (Fig. 1B, arrows) but not in all cells (Fig. 1F). To 
show that ΔNES was indeed in both the nucleus and the cytoplasm, we obtained optical sections 
through cells transfected with ΔNES and confirmed that the distribution of FMRP was between 
both the nucleus and the cytoplasm (Fig. 1C). One major conclusion is that the majority of the 
transfected cells exhibit cytoplasmic EGFP-FMRP even in the absence of the NES (Fig. 1B, C, 
and F). There are at least three possible explanations for this result. The first is that the NES is 
inactive in these cells. We do not suspect that this is the case because the NES was functionally 
defined in Cos-7 cells by conjugating it to bovine serum albumin and then showing that the 
nuclear injected fusion protein could be exported (24). The second possibility is that there are 
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two distinct populations of FMRP, with the majority being exclusively cytoplasmic. The third 
possibility is that FMRP is efficiently exported out of the nucleus by a mechanism that is 
independent of its NES. 
 The NLS of FMRP is not a classical NLS (39); thus, the molecular requirements for its 
activation are not well understood. To address the possibility that only a fraction of the FMRP 
enters the nucleus, we attempted to direct all of the expressed EGFP-FMRP to the nucleus by 
adding the autonomous NLS of the SV40 large T antigen (47, 48) to the N terminus of FMRP. 
Surprisingly, while the SV40 NLS is a strong nuclear import signal, it did not significantly 
increase the amount of steady-state nuclear SV40-FMRP (Fig. 1D and F), and the percentage of 
cells with primarily nuclear SV40-FMRP was essentially unchanged (Fig. 1F). The SV40 NLS 
was effective because the removal of the NES from SV40-FMRP resulted in an increased 
number of cells in which the newly expressed protein was evenly distributed between the 
cytoplasm and the nucleus (Fig. 1E [arrows] and F). However, the percentage of cells where 
SV40-FMRP ΔNES (SV40-ΔNES) was exclusively nuclear only increased to 12% (Fig. 1F). The 
same results were obtained when the constructs were expressed in HeLa cells (data not shown). 
Together, these data strongly suggest the existence of an efficient mechanism—distinct from the 
NES-dependent export pathway—that is primarily responsible for the nuclear export of FMRP. 
 
 Tap/NXF1 knockdown increases the nuclear accumulation of FMRP. 
 FMRP binds a large collection of mRNAs (12, 58) and has been estimated to associate 
with approximately 4% of brain mRNAs (6). We hypothesized that if FMRP enters the nucleus 
to bind mRNAs, then the bound mRNAs themselves might direct export through their 
association with the bulk mRNA exporter Tap/NXF1. To determine whether Tap/NXF1 is 
involved in the export of FMRP from the nucleus, we developed four siRNAs against Tap/NXF1 
that were specific for Tap/NXF1 by a BLAST search (data not shown). Administered as a 
cocktail of all four siRNAs (Fig. 2A, lane All) or individually (Fig. 2A, lanes 1 to 4), the 
Tap/NXF1 siRNAs greatly reduced Tap/NXF1 expression in cells by 67 to 91% compared to that 
of the mock-treated cells, based on densitometry (Fig. 2A). Further, serial dilutions of the mock-
treated cell extracts shown on the right in Fig. Fig.2A2A verify that all of the Tap/NXF1 siRNA 
treatments did indeed reduce Tap/NXF1 expression levels by more than 70%. 
40 
 
 To examine the role of Tap/NXF1 in the export of FMRP from the nucleus, we treated 
EGFP- or SV40-FMRP-expressing cells with these siRNAs. Treatment with the irrelevant 
siRNA resulted in very few cells showing predominantly nuclear expressions of FMRP (Fig. (Fig. 
2B and the first bars of E and F, respectively). Approximately 0.4% of the EGFP-FMRP-
expressing cells and 2% of the SV40-FMRP-expressing cells were primarily nuclear. In contrast, 
the treatment of EGFP-FMRP-expressing cells with pooled siRNAs or the individual siRNAs 
significantly increased the number of cells with nuclear EGFP-FMRP to nearly 5%, which was a 
10-fold increase over treatment with an irrelevant siRNA (Fig. 2E). The treatment of cells 
expressing SV40-FMRP with Tap siRNAs also resulted in a 10-fold increase in the number of 
cells expressing predominantly nuclear FMRP (Fig. 2C, D, and F). Because more SV40-FMRP 
was directed to the nucleus, the percentage of cells expressing primarily nuclear FMRP after Tap 
siRNA treatment was as high as 34.5% (Fig. 2F). Similarly to the results observed in Fig. 1F, the 
SV40 NLS was much more efficient at directing FMRP into the nucleus than the native protein 
(compare Fig. 2E and F). However, both populations of transfected cells showed a significant 
increase in the number of cells expressing FMRP in the nucleus after the reduction of Tap/NXF1 
expression, underscoring the importance of this protein in the nuclear export of FMRP. 
 
SV40-FMRP is localized in the nucleus. 
 To ensure that SV40-FMRP was indeed localized inside the nucleus and not on the outer 
nuclear membrane, we live imaged transfected cells using confocal microscopy. Figure 
Figure2G2G shows the nuclear expression of SV40-FMRP in Tap 2 siRNA-treated cells that 
were counterstained with the cytoplasmic stain BODIPY that labels endoplasmic reticula, Golgi 
bodies, and mitochondria, leaving the nuclei unstained (4, 82). SV40-FMRP is present in the 
nuclei and, in some cases, subnuclear structures (Fig. 2G). Thus, under conditions of reduced 
Tap/NXF1 expression, FMRP accumulates in the nucleus, suggesting that FMRP binds mRNAs 
in the nucleus and that the complex is exported by Tap/NXF1. 
 
The endogenous NLS directs a significant amount of FMRP into the nucleus. 
 To examine the efficacy of the endogenous NLS, we examined the effects of removing 
both the NES- and the Tap/NXF1-mediated export pathways. We found that about 5% of the 
cells expressing ΔNES were nuclear and 39% had ΔNES evenly distributed between the nucleus 
41 
 
and the cytoplasm (Fig. 3, middle bars). When the ΔNES-expressing cells were treated with 
Tap/NXF1 siRNA, the number of cells with primarily nuclear expression of ΔNES increased to 
7.6% and there was a further increase in the fraction of cells showing an even distribution of 
ΔNES between the nucleus and the cytoplasm from 39% to 57% (Fig. 3, right bars). Thus, 
blocking both nuclear export pathways led to the redistribution of FMRP from its primarily 
cytoplasmic distribution to one where the majority of cells (57%) expressed ΔNES evenly 
between the nucleus and the cytoplasm and 7.6% of the cells expressed ΔNES primarily in the 
nucleus. We conclude that a significant amount of FMRP enters the nucleus using the 
endogenous NLS. 
 
 Removal of the NLS leads to compromised RNA binding 
 
 If the endogenous NLS were indeed required for nuclear entry leading to subsequent 
RNA binding, we reasoned that its removal should result in a loss of FMRP from polyribosomes. 
We removed the 40 amino acid NLS from FMRP (ΔNLS), which is encoded within exon 5, and 
examined whether association with polyribosomes was affected, as evidence for a functional 
association with mRNAs (Fig. 4B). The removal of the NLS led to a 50% loss of FMRP from 
polyribosomes to the messenger RNP fractions compared to that of EGFP-FMRP (compare Fig. 
4A and B). Initially, this result seemed like indirect evidence that FMRP bound mRNAs in the 
nucleus. However, we wanted to establish that ΔNLS had not lost the ability to bind RNAs 
because of the deletion. When we compared the ability of in vitro-synthesized EGFP-FMRP and 
ΔNLS to bind a G quartet bearing RNA (sc1) through the distal, C-terminal RNA binding 
domain, the RGG box (encoded within exon 15), we found ΔNLS to be severely compromised 
(Fig. 4C), suggesting that the ΔNLS protein is partially misfolded. Further, ΔNLS is unable to 
associate with the known binding partner autosomal paralog FXR1 in cells (Fig. 4D), whose 
binding site is encoded by exon 7 (72). Thus, the removal of the NLS in the N-terminal part of 
the protein led to a reduced ability to bind RNAs and FXR1, whose interaction sites are more 
distally located, suggesting that amino acids 110 to 151 are critical for the normal folding and 
function of FMRP. 
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Tap/NXF1 knockdown increases the nuclear accumulation of SV40-ΔNES. 
 To examine the combined effects of the NES and Tap/NXF1 on cells in which all of the 
FMRP is directed to the nucleus, we examined the effect of Tap reduction on nuclear localization 
using cells expressing SV40-ΔNES. As shown earlier, most of the cells expressing SV40-ΔNES 
had FMRP evenly distributed between the nucleus and the cytoplasm (55%). To verify that 
indeed the SV40-ΔNES cells were expressing FMRP in both the nuclear and cytoplasmic 
compartments, we also performed confocal microscopy on the cells (Fig. 5B). We also found 
that approximately 12% of the SV40-ΔNES-expressing cells treated with an irrelevant siRNA 
were primarily nuclear (Fig.1 and 5A and B). In contrast, treatment with either Tap 1 or Tap 2 
siRNAs greatly increased the number of cells expressing primarily nuclear FMRP to 42% and 
51%, respectively (Fig. 5C, D, and E). Accordingly, the amount of cells expressing SV40-ΔNES 
primarily in the cytoplasm decreased from 33% to 10% after Tap siRNA treatment (Fig. 5E, 
middle bars). Thus, FMRP can exit the nucleus through its NES, as well as by a Tap-mediated 
export pathway—presumably through its bound mRNAs—supporting our hypothesis for two 
mechanisms of export: one encoded by the NES of FMRP and the other by the bulk mRNA 
exporter Tap/NXF1. 
 
Validation of the cell scoring method by directly quantifying the intracellular fluorescence. 
 To verify that quantifying the percentage of cells expressing EGFP-FMRP as nuclear, 
cytoplasmic, or evenly distributed was consistent, we determined the ratio of total nuclear 
fluorescence to total cellular fluorescence on a significant number of cells from each treatment 
type (Fig. 5F). For cells that were scored as cytoplasmic (Fig. 5F), approximately 13% of the 
total fluorescence was in the nucleus, and none of the treatment groups were significantly 
different from one another, with the exception of the cytoplasmic cells in the SV40-ΔNES 
Tap/NXF1, which had an increased amount of fluorescence in the nucleus (17%). For cells that 
were scored as nuclear (Fig. 5F), approximately 38% of the fluorescence was in the nucleus, 
which was significantly different from both the cytoplasmic and evenly distributed cells. All 
cells expressing EGFP-FMRP primarily in the nucleus had the same percentage of their 
fluorescence in the nucleus, regardless of the type of treatment and were not significantly 
different from one another. For cells that were described as evenly distributed, which were only 
observed when the NES was removed (Fig. 5F), approximately 24% of the fluorescence was 
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found in the nucleus. Thus, this quantification shows that the scoring of cells as nuclear, evenly 
distributed, or cytoplasmic represents distinct and reproducible subpopulations of cells in these 
experiments. 
 
 The nuclear association of FMRP is RNA mediated. 
 Our hypothesis is that FMRP enters the nucleus to bind mRNAs, which then facilitate the 
export of the complex through the Tap/NXF1 pathway. Therefore, in the absence of Tap/NXF1, 
SV40-FMRP retained in the nucleus should be bound to RNA. To test this prediction, Cos-7 
cells transfected with SV40-FMRP and Tap 2 siRNA were treated with RNase A, which can 
freely diffuse into the nucleus of permeabilized cells. We then examined the number of cells 
expressing nuclear SV40-FMRP. The permeabilization of the cytoplasmic membrane in the 
absence of RNase A did not alter the nuclear or cytoplasmic localization of SV40-FMRP (Fig. 
6A). Although the Triton X-100 treatment did moderately affect the morphology of the nucleus 
(Fig. 6A, top panels), it did not influence the percentage of cells expressing nuclear SV40-FMRP 
compared to that of CSK buffer-treated cells (Fig. 6C). In contrast, RNase A treatment 
significantly reduced the number of cells expressing SV40-FMRP primarily in the nucleus from 
36.6% to 11.9% (Fig. 6B and C). RNase A treatment did not affect SV40-FMRP-containing 
granules in the cytoplasm (Fig. 6B). Our data show that in the absence of Tap/NXF1, SV40-
FMRP is retained in the nucleus in an RNA-dependent manner. 
 Using siRNAs directed to Tap/NXF1, we have established a functional relationship 
between Tap/NXF1 and FMRP. To determine if FMRP associates with Tap/NXF1 in an RNA-
dependent manner, we immunoprecipitated EGFP-FMRP or SV40-FMRP with 7G1-1, an 
antibody that robustly recognizes murine FMRP (12). The immunoprecipitated complex was 
then treated with RNase to disrupt any RNA-mediated complexes and examined for the presence 
of endogenous Tap/NXF1. We found that Tap/NXF1 did indeed coimmunoprecipitate with 
EGFP-FMRP and SV40-FMRP in an RNA-dependent manner (Fig. 6D). 
 To eliminate the possibility of the postlysis association of FMRP and Tap/NXF1, we 
chemically cross-linked mock-transfected cells or cells expressing Flag-Tap with one of the 
following constructs: EGFP-FMRP, SV40-FMRP, or the FMR point mutation I304N (20). The 
expression of the transgenes is shown in Fig. 6E (left panel) because both the Tap/NXF1 and 
FMRP constructs contain the Flag epitope. Upon the immunoprecipitation with the 7G1 antibody, 
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we found that EGFP-FMRP, SV40-FMRP, and I304N all associate with Tap/NXF1 (Fig. 6E, 
right panel). Like FMRP, Tap/NXF1 is also found on polyribosomes (45). The I304N mutant 
shuttles rapidly between the nucleus and cytoplasm more so than EGFP-FMRP (78), likely 
because it is not captured on polyribosomes. Since I304N is present in the nucleus but not on 
polyribosomes (29), the association of Tap/NXF1 with I304N provides evidence that  
Tap/NXF1 interaction with FMRP does not occur on polyribosomes. 
 Only proteins within close proximity to one another are cross-linked, as we were unable 
to find eIF5, an abundant but nonassociated protein, in the immunoprecipitations (data not 
shown). We conclude that Tap/NXF1 and FMRP do associate in cells and that this interaction 
does not occur on polyribosomes. 
 
Tap/NXF1 associates with FMRP in a complex with FMR1 mRNA. 
 Our hypothesis is that FMRP enters the nucleus to associate with its cargo mRNAs, 
which then facilitate the export of the FMRP-mRNA complex through association with the bulk 
mRNA exporter Tap/NXF1. Although two large lists of FMRP mRNA cargoes have been 
described (12, 58), the association with FMR1 mRNA has been the most extensively 
characterized (3, 6, 13, 69). In fact, just recently FMRP was described as modulating the splicing 
of its own mRNA (23). To determine whether the FMRP-Tap/NXF1-FMR1 mRNA complex 
exists, we undertook the sequential immunoprecipitation strategy shown in Fig. 7A to capture the 
FMRP-Tap/NXF1 complex. After cross-linking mock-transfected Cos-7 cells or Cos-7 cells 
either expressing EGFP-FMRP or cotransfected with both EGFP-FMRP and Flag-Tap (Fig. 7B), 
we immunoprecipitated EGFP-FMRP with the 7G1-1 antibody. After being extensively washed, 
the FMRP-containing complexes were eluted using the FMRP peptide that is recognized by 7G1-
1 (12). The released FMRP-containing complexes were then reimmunoprecipitated with the anti-
Tap antibody that immunoprecipitates Tap/NXF1 (Fig. 7C) to isolate EGFP-FMRP-Flag-
Tap/NXF1 complexes. RNA was isolated from the FMRP-Tap/NXF1 complex and found to 
contain FMR1 mRNA (Fig. 7D), which was also present in the peptide elution from the EGFP-
FMRP immunoprecipitation but not from the mock immunoprecipitation. We conclude that 
FMRP associates with Tap/NXF1 in a complex that contains FMR1 mRNA that is known to bind 
FMRP, providing further evidence that FMRP and Tap/NXF1 associate in an mRNA-dependent 
complex. 
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Nuclear EGFP-SV40-Flag-FMRP is not recognized efficiently by the anti-FMRP antibody 1a 
by immunostaining. 
 In the studies presented here, all of the cellular assays were done with EGFP-FMRP. We 
also tried to examine the effect of Tap/NXF1 knockdown on endogenous FMRP localization in 
Cos-7 cells. To our surprise, we found that the anti-FMRP antibody 1a, which has effectively 
been used for immunostaining (22) and Western blotting, including the detection of the FMRP 
encoded by the constructs used here (75), did not consistently identify nuclear FMRP by 
immunostaining. We first attempted to immunostain endogenous FMRP in Tap/NXF1 siRNA-
treated Cos-7 cells and saw only cytoplasmic staining (data not shown). To be sure that we were 
using the optimal staining conditions for the nuclear FMRP, we stained Tap/NXF1 siRNA-
treated, SV40-FMRP-expressing cells with either the Flag antibody (Fig. 8B, red), which 
recognizes nuclear SV40-FMRP, or with the 1a antibody (Fig. 8A, red), which shows 
cytoplasmic staining. That SV40-FMRP is indeed in the nucleus is shown by the EGFP staining 
(green in Fig. 8A and B). Thus, unlike the N-terminal Flag epitope, perhaps the 1a epitope is 
inaccessible or buried in the nucleus. 
 
FMRP associates with nascent transcripts in amphibian oocytes. 
 At this point, our data suggest that FMRP binds mRNAs in the nucleus because of a 
functional and RNA-mediated association with Tap/NXF1. To directly ask whether FMRP binds 
nascent mRNAs, we adopted the most tractable system for examining messenger RNP formation 
on transcripts: the LBCs of amphibian oocytes. LBCs are extended bivalent chromosomes, 
characterized by the presence of numerous lateral loops along the length of each homolog 
(reviewed in reference 60). Each chromosomal loop is composed of a DNA axis that is actively 
transcribed by RNA polymerase II and from which are elongating, tightly packed, nascent 
ribonucleoprotein (RNP) fibrils. We transcribed the HA-SV40-WT FMR1 mRNA in vitro, 
injected the RNA into the cytoplasm of stage V oocytes, and monitored the fate of the newly 
made HA-SV40-FMRP by indirect immunofluorescence on nuclear spreads. We found that HA-
SV40-FMRP associates with nascent RNP fibrils on LBCs (Fig. 9B). We used the rat 
monoclonal antibody 3F10 because its high-affinity binding precludes nonspecific recognition (8, 
66). Interestingly, the labeling of any given loop does not correspond to a homogenous signal 
over its length, as is usually the case for many other RNPs (8). Rather, the signal appears 
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discontinuous and specific for granular complexes on the loops (Fig. 9B and D). Overall, HA-
SV40-FMRP staining was generally weak but specific compared to LBCs from uninjected 
control oocytes (Fig.9F), possibly due to the fact that this is a heterologous system where murine 
FMRP is bound to Xenopus proteins and transcripts. We also observed the presence of HA-
SV40-FMRP in the nucleoli and Cajal bodies, with a general preference for association with 
Cajal bodies (data not shown). 
 To determine whether endogenous Xenopus FMRP is also present on LBCs, we stained 
nuclear spreads of uninjected oocytes with an antibody directed against Xenopus FMRP (9). 
Figure 10B and D show that anti-FMRP labeled the chromosomal loops, strongly suggesting that 
endogenous FMRP associates with nascent transcripts. A control stain using a preimmune serum 
showed no staining above the background (Fig. 10F), suggesting that the FMRP staining was 
specific for endogenous FMRP. 
 We used two independent approaches to examine whether FMRP associates with mRNAs 
in the nucleus. First, we showed that reduction of the primary mRNA exporter resulted in a 
significantly higher number of cells expressing EGFP-FMRP and SV40-FMRP in the nucleus 
and that both EGFP-FMRP and SV40-FMRP associate with Tap/NXF1 in an mRNA-containing 
complex. Second, using two different antibodies, we showed that HA-SV40 FMRP and 
endogenous Xenopus FMRP are present on nascent transcripts on LBCs. Together, these data 
provide the first evidence that FMRP binds mRNAs in the nucleus. 
 
2.4 Discussion 
Role of Tap/NXF1 on the export of FMRP from the nucleus. 
 Tap/NXF1 was originally characterized as the exporter of retroviral RNAs bearing a CTE 
(11, 36, 49). Tap/NXF1 has since been identified as the primary exporter of mRNAs (reviewed 
in references 15, 44, 56, 61, and 80). Although Tap/NXF1 has an RNA binding domain, it is of 
relatively low affinity (49). Thus, there are two mechanisms by which Tap/NXF1 is proposed to 
export mRNAs: the first is by directly binding the CTE-like elements in the mRNAs themselves; 
the second is by directly interacting with proteins bound to the mature mRNA (41, 42). At this 
time, we are not certain through which of these mechanisms Tap/NXF1 mediates the export of 
FMRP-mRNA complexes. CTEs have been found in mammalian genes, specifically, in the 
Tap/NXF1 gene itself (55) and in the Wilms' tumor gene (10). It is possible that some of the 
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RNAs bound by FMRP contain a CTE; alternatively, and probably more likely, the mRNAs 
bound by FMRP are also bound by proteins associated with mature splicing like the exon 
junction complex component Aly/Ref (52, 53), which directly associate with Tap/NXF1 (76). 
 Although we observed that both the NES and Tap/NXF1 were critical for the export of 
FMRP from the nucleus, we were unable to identify a condition where all of the cells expressed 
exclusively nuclear FMRP, leading one to speculate on how FMRP exits the nucleus efficiently 
in the rest of the cells. One possible explanation is that any residual Tap/NXF1 expression in 
cells after siRNA treatment facilitates export. It is also possible that other export factors facilitate 
the export of FMRP. NXF2, another NXF family member, has highly conserved architecture and 
is also capable of mRNA export (79). In fact, NXF2 has been shown to associate with FMRP and 
is also present in testes and brain (79, 87). NXF2 has also been proposed to destabilize 
Tap/NXF1 mRNA when associated with FMRP (87). Perhaps in cells where FMRP and NXF2 
are expressed, a reduction in Tap/NXF1 expression is desirable to either increase the nuclear 
accumulation of FMRP or permit the association of FMRP with NXF2 in the absence of 
Tap/NXF1. Primarily found in the brain and testes and not highly expressed in cells used in 
tissue culture, NXF2 may perform tissue-specific functions that likely have not influenced the 
function of Tap/NXF1 in our experiments. 
 
FMRP and Tap/NXF1 functionally associate. 
 In addition to that shown in our study, a functional association between Tap/NXF1 and 
FMRP has already been shown to occur during Drosophila development (59). The small bristles 
gene encodes the Drosophila ortholog of Tap/NXF1 (85). During cleavage furrow formation, 
blocking Tap/NXF-1 expression using the conditional small bristles mutant results in a dramatic 
change in the cytoplasmic state of Drosophila FMRP. In the absence of exported zygotic 
transcripts, Drosophila FMRP moves from relatively diffuse punctate structures to large 
polymorphic structures. Thus, the cytoplasmic particles containing Drosophila FMRP are 
dynamic in response to new transcripts (59). 
 In the studies mentioned earlier, it was suggested that FMRP interacts with the Tap/NXF 
family member NXF2 but not with Tap/NXF1 (51, 87). This conclusion was drawn in part from 
the inability to coimmunoprecipitate Tap/NXF1 with FMRP. Our study differs from that work in 
two ways: (i) we used a robust FMRP-immunoprecipitating antibody, 7G1-1, to capture FMRP 
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complexes (12) in contrast to the antibody used for the studies described previously (51, 87), 
which has been characterized as working only for immunostains and Western blots (14, 19, 22), 
and (ii) we suspect that the association with FMRP is transient and likely mediated by RNA. We 
found that FMRP and Tap/NXF1 do indeed associate in an mRNA-containing complex that is 
captured using cross-linking and disrupted upon RNase treatment. More importantly, in addition 
to demonstrating a physical association, we show a functional effect of the loss of Tap/NXF1 on 
FMRP localization in cells. 
 
FMRP's NLS. 
 We showed that the reduction of Tap/NXF1 in cells expressing EGFP-FMRP resulted in 
the nuclear accumulation of FMRP and that the removal of both Tap/NXF1 and the NES led to 
the majority of cells expressing some FMRP in the nucleus. Thus, FMRP's endogenous NLS is 
functional, as has been reported before (24); however, the SV40 NLS is much more efficient at 
directing FMRP into the nucleus. One explanation for the relative weakness of FMRP's NLS 
might be that it requires additional factors to be activated. Perhaps cell-type or cell-cycle-specific 
proteins facilitate the nuclear import of FMRP under specific conditions, as in the early stages of 
Xenopus and zebrafish development when FMRP is primarily nuclear (9, 81). In contrast, the 
removal of FMRP's NLS led to an improperly functioning protein that could not be evaluated for 
its ability to traffic in cells. Naturally occurring splice variants of FMRP retain normal protein 
function after the removal of some domains like the RGG box and the NES (5, 26), suggesting 
that FMRP behaves more modularly in the C terminus. 
 In conclusion, prior studies established that FMRP resides in the nucleus under certain 
conditions, although it was not known what its function was there. It has been long speculated 
that FMRP binds its mRNA cargoes in the nucleus, but the evidence has been lacking. By 
demonstrating a functional and physical association with the primary RNA exporter Tap/NXF1 
and also by visualizing FMRP association with the LBCs, we provide the first evidence that 
FMRP can enter the nucleus to bind its mRNA cargoes. 
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2.5 Figures. 
 
Figure 2.1. FMRP is efficiently exported from the nucleus in the absence of an NES and in 
the presence of the SV40 NLS. Cos-7 cells were plated and transfected with constructs 
expressing EGFP-FMRP (WT) (A); EGFP-FMRP with the NES deleted (ΔNES) (B, C); EGFP-
SV40-FMRP (SV40-FMRP) (D); and EGFP-SV40-ΔNES (SV40-ΔNES), fixed in DAPI-
containing mounting medium and imaged for the expression of EGFP-FMRP (green, left panels) 
and nuclei (blue DAPI stain, middle panels) and for the merged EGFP and DAPI images (right 
panels) (E). The arrows in panel B indicate cells expressing ΔNES in the nucleus. Panel C shows 
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ΔNES-expressing cells examined by optical sectioning as described in Materials and Methods. 
The arrows in panel E indicate cells expressing comparable amounts of SV40-ΔNES in the 
nucleus and cytoplasm. (F) Cos-7 cells expressing EGFP-FMRP (WT), ΔNES, SV40-FMRP 
(SV40), and SV40-ΔNES were scored for the percentage of cells with a nuclear accumulation of 
FMRP. The results of individual experiments, where over 100 cells were scored each time, were 
averaged to find the percentage of cells with nuclear accumulation of FMRP for each construct. 
The WT and SV40 constructs were scored for primarily nuclear FMRP, while ΔNES and EGFP-
SV40-ΔNES were scored for cells that demonstrated primarily nuclear, primarily cytoplasmic, or 
evenly distributed FMRP between the nucleus and cytoplasm (even). 
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Figure 2.2. The reduction of Tap/NXF1 expression results in the nuclear accumulation of 
EGFP-FMRP and SV40-FMRP. (A) Cos-7 cells were mock treated with an irrelevant siRNA 
(M) or treated with a mixture of the four siRNAs against Tap/NXF1 (All) at a final concentration 
of 100 nM or individually with each of the four Tap/NXF1 siRNAs (1 to 4). Forty-eight hours 
later, the lysates were prepared and 75 μg of each were resolved on 7.5% SDS-polyacrylamide 
gel electrophoresis gels. The last three lanes contain dilutions of the mock: 50% (37.5 μg), 25% 
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(18.8 μg), and 12.5% (9.4 μg). The blot was probed with affinity-purified anti-Tap antisera and 
reprobed with anti-eIF-5 as a loading control. The amount of Tap per lane was calculated using 
NIH Image and shown as the percent reduction from the mock. (B to D) Cos-7 cells were 
transfected with SV40 FMRP and the siRNAs indicated as follows: an irrelevant siRNA (B), a 
mixture of the four Tap/NXF1 siRNAs (Tap All) (C), and Tap/NXF1-2 siRNA (D). The cells 
were imaged for the expression of EGFP (green, left panels) and nuclei (blue DAPI stain, middle 
panels), and the EGFP and DAPI images were merged (right panels). (E, F) Cos-7 cells 
transfected with either EGFP-FMRP (E) or EGFP-SV40-FMRP (F) and treated with either the 
irrelevant siRNA, a mixture of the four Tap/NXF1 siRNAs (Tap All), or the individual 
Tap/NXF1 siRNAs (Tap 1 to 4) for 48 h and scored for the percentage of cells with a primarily 
nuclear accumulation of FMRP. The percentage of cells expressing FMRP in the nucleus is 
indicated by each bar. The results were plotted using GraphPad Prism 4. Significance was 
calculated using a one-tailed Student's t test. A single star indicates a P of <0.05, and two stars 
indicate a P of <0.01. (G) Cos-7 cells were transfected with SV40 FMRP and the Tap/NXF1-2 
siRNA. Twenty-four hours later, the cytoplasmic counterstain CellTrace BODIPY TR methyl 
ester (Invitrogen) was added, and the cells were live imaged with a confocal microscope at ×63 
magnification with oil for EGFP (green, left panels) and cytoplasm stain (blue, middle panels), 
and the EGFP and BODIPY images were merged (right panels). 
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Figure 2.3. The endogenous NLS of FMRP directs a significant amount of EGFP-ΔNES 
into the nucleus. Cos-7 cells were transfected with either EGFP-FMRP (WT) or ΔNES with 
irrelevant siRNA (ΔNES) or with Tap/NXF1-2 siRNA (ΔNES Tap). The cells were imaged and 
scored for nuclear, cytoplasmic, or even distribution between the nucleus and cytoplasm. Five 
independent experiments were scored and plotted using GraphPad Prism 4. 
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Figure 2.4. Removal of the NLS impairs the function of FMRP. Immortalized Fmr1 knockout 
fibroblast cells (STEK) (57a) were transfected with EGFP-FMRP (WT) (A) or EGFP-FMRP in 
which the endogenous NLS has been removed (ΔNLS) (B), treated with cycloheximide, and 
fractionated on a linear 15 to 45% sucrose gradient. Profiles are shown as the absorbance at 254 
nm, and the position of the 80S monosome is indicated at the top of each gradient. Fractions 
were analyzed on 7.5% gels, transferred to polyvinylidene difluoride and probed with the anti-
FMRP antibody 1a to visualize transgene expression (top row), FXR1 (middle row), or eIF5 
(bottom row). The amount of FMRP in each fraction was quantified using NIH Image. Removal 
of the NLS led to a loss of ∼50% of the polyribosome-associated FMRP. (C) EGFP-FMRP or 
ΔNLS expressed in pSport were transcribed and translated in vitro and used in a biotinylated 
RNA capture assay (75). sc1 is an RNA encoding a G quartet, and the sc1 mutant (sc1 mut) is an 
RNA encoding a G quartet mutant unable to bind the RGG box of FMRP (18). (D) STEK cells 
transfected with either EGFP-FMRP (WT) or ΔNLS transgenes were fractionated into either a 
postnuclear supernatant (cyto) or pelleted again (P1). FMRP was immunoprecipitated from each 
fraction and blotted for FXR1 or FMRP as indicated on the right. STEK extract was loaded as a 
control (ext), and the immunoprecipitating immunoglobulin chains (Ig) are indicated. 
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Figure 2.5. Tap/NXF1 knockdown increases the nuclear accumulation of SV40-ΔNES. (A to 
D) Cos-7 cells were plated and transfected with SV40-ΔNES and the siRNAs indicated and 
imaged for the expression of EGFP-SV40-ΔNES (green, left panels) and nuclei (blue DAPI stain, 
middle panels); the EGFP and DAPI images were merged (right panels) by inverted fluorescence 
microscopy (A, C) and by confocal microscopy (B, D). (E) Three independent experiments were 
scored for cells that expressed transgene primarily in the nucleus (nuclear), primarily in the 
cytoplasm (cytoplasmic), or evenly distributed between the nucleus and cytoplasm (even) after 
treatment with an irrelevant siRNA (irrel) or Tap 1 or 2 siRNA. The average percentage of cells 
is given at the bottom of the bar. The results were plotted using GraphPad Prism 4. Significance 
was calculated using a one-tailed Student's t test. A single star indicates a P of <0.05, two stars 
indicate a P of <0.01, and three stars indicate a P of <0.005. (F) Consistency of cell scoring was 
evaluated by calculating the ratio of total nuclear fluorescence to total cellular fluorescence and 
performing a one-way analysis of variance using an α value of 0.05. Cells scored as cytoplasmic 
had an average nuclear fluorescence of 12.93% ± 2.12%, while cells scored as even had an 
average nuclear fluorescence of 23.37% ± 4.57% and nuclear cells had average nuclear 
fluorescence of 38.29% ± 3.65%. All P values were less than 0.05, and many were less than 
0.001, with the exception of the SV40-ΔNES cells treated with Tap/NXF1. 
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Figure 2.6. The retention of EGFP-FMRP in the nucleus in the absence of Tap/NXF1 is 
RNA dependent. Cos-7 cells were plated and transfected with SV40-FMRP and Tap/NXF1-2 
siRNA, permeabilized with 0.05% Triton (A) (top, cells expressing SV40-FMRP in the nucleus; 
bottom, cells expressing SV40-FMRP in the cytoplasm), and treated with RNase (B). (C) The 
percentage of cells expressing FMRP in the nucleus is indicated by each bar. The results were 
plotted using GraphPad Prism 4. (D) Cos-7 cells were either untransfected (M) or transfected 
with EGFP-FMRP (WT) or SV40-FMRP (SV40) (WCL, whole cell lysate [50 μg/lane]), 
immunoprecipitated (IP) with the anti-FMRP antibody 7G1-1, washed with buffer containing 
RNase (+) or not (−) and immunoblotted for endogenous Tap/NXF1 (Tap) 
coimmunoprecipitation and FMRP transgene (bottom). Non-sp, reactivity to an irrelevant protein; 
Ig, immunoprecipitating antibody alone; ib, immunoblot. (E) Cos-7 cells were either mock 
transfected (M) or transfected with Flag-Tap/NXF1 (F-Tap) alone or with Flag-Tap/NXF1 and 
one of the following constructs: FMRP (WT), SV40-FMRP (SV40), or I304N. Cells were treated 
with 0.5% formaldehyde and sonicated as described in Materials and Methods. Left panel, 35 μg 
of the lysates were loaded, resolved, and probed for transfection efficiency with the anti-Flag 
antibody (M2; Sigma) to visualize EGFP-FMRP expression (these constructs contain the Flag 
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epitope) and Flag-Tap/NXF1; the eIF5 immunoblot (ib) shows equal loading. Right panel, 
immunoprecipitation with the anti-murine FMRP antibody 7G1-1. Immunoprecipitated FMRP 
was visualized using the anti-FMRP antibody K1, and Flag-Tap coimmunoprecipitation was 
visualized by a rabbit anti-Tap antibody. 
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Figure 2.7. Tap/NXF1 associates with FMRP in a complex with FMR1 mRNA. (A) 
Schematic showing the reimmunoprecipitation experiment. Transfected cells were treated with 
formaldehyde (cross-linked) and then immunoprecipitated with the anti-FMRP antibody 7G1-1. 
Immunoprecipitated complexes were eluted with the 7G1-1 peptide and reimmunoprecipitated 
(Re-IP) with an anti-Tap antibody. RNA was extracted and analyzed from the complex. (B) Cos-
7 cells were mock-transfected (m) or transfected with EGFP-FMRP (WT) or EGFP-FMRP and 
Flag-Tap (WT Tap) and immunoblotted (ib) with an anti-Flag antibody (Flag). (C) The anti-
Tap/NXF1 antibodies immunoprecipitate with ∼15% efficiency. Cos-7 cells were mock 
transfected (m) or transfected with Flag-Tap (F-Tap); 50 μg was loaded per lane (wcl, whole cell 
lysate). Two different anti-Tap/NXF1 antibodies (IP-1 and IP-2) were used to immunoprecipitate 
extracts from mock or Flag-Tap-expressing cells. (D) FMRP immunoprecipitations (IP) from 
mock-treated Cos-7 cells (m), EGFP-FMRP-expressing Cos-7 cells (WT), or EGFP-FMRP- and 
Flag-Tap/NXF1-expressing Cos-7 cells (WT Tap) were peptide eluted. RNA was extracted from 
mock and WT peptide elutions. The peptide elution from WT Tap was reimmunoprecipitated 
with the anti-Tap/NXF1 antibody from which the RNA was extracted. First-strand synthesis was 
performed, followed by PCR for FMR1 mRNA. +, RT-PCR from Cos-7 cell total RNA. 
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Figure 2.8. Nuclear EGFP-SV40-Flag-FMRP is not recognized by the anti-FMRP antibody 
1a. Cos-7 cells were transfected with SV40-FMRP and Tap siRNAs (Tap All), fixed, and 
permeabilized as described previously (57). The cells were stained with either the anti-FMRP 
antibody 1a (22) (A) or the anti-Flag antibody (M2) (B). Nuclear EGFP SV40-FMRP was 
observed using the green channel (left images) and by Flag staining (middle image in panel B); 
however, it was not detected by antibody 1a (middle image in panel A). Right images show 
merged DAPI staining with EGFP and anti-mouse rhodamine (red). 
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Figure 2.9. FMRP associates with LBCs in the nucleus. Stage V Xenopus laevis oocytes were 
injected with HA-SV40-WT FMRP cRNA. Nuclear spreads were prepared 24 to 48 h after 
injection, and the localization of FMRP was visualized using fluorescence microscopy. (A) The 
phase contrast image shows an LBC and associated proteins. (B) Chromosomal spreads were 
incubated with anti-HA antibody and visualized by fluorescence microscopy. FMRP is localized 
along the DNA axis and is also seen along chromosomal loops (arrows) in green. (C) 
Chromosomes were counterstained using DAPI and false colored in red. (D) Merged images of 
chromosomes and FMRP localization demonstrate that FMRP is associated with the LBCs and 
along a subset of chromosomal loops. The scale bar represents 5 mm. (E) Uninjected control 
oocytes were prepared in parallel to injected oocytes. The phase contrast image shows a single 
chromosome. (F) Anti-HA antibody staining. (G) Counterstaining using DAPI and false coloring 
in red. 
  
61 
 
 
Figure 2.10.  Endogenous FMRP associates with nascent transcripts in the nucleus. 
Xenopus oocytes were stained with the anti-Xenopus FMRP antibody K1. (A) A ×40 
magnification of a single chromosome visualized in phase contrast. (B) FMRP (green) is 
localized with the LBCs. The DNA axis is shown in red. (C) A ×100 magnification shows 
single-stranded loops (indicated by arrows) of DNA extending off the axis in phase contrast. 
Scale bar represents 2 mm. (D) FMRP (green) is localized with the LBCs. The DNA axis is 
shown in red. Phase contrast of an LBC (E), stained with rabbit preimmune antisera (F), and 
counterstained using DAPI and false colored in red (G). 
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2.6 Experimental Procedures 
 
Cell lines, transfections, and DNA constructs. 
Cells were grown at 37°C in 5% CO2 in Dulbecco's minimal essential medium containing 10% 
fetal calf serum supplemented with 10 mM HEPES, 1× nonessential amino acids (Biowhittaker, 
Walkersville, MD) (complete medium). Cotransfections of small interfering RNAs (siRNAs) and 
plasmids were performed as described previously (27). Briefly, 5 × 104 Cos-7 cells were plated 
in 1 ml per chamber of a four-chamber culture slide (BD Falconwell) or in 1 well of a 24-well 
dish. The next day, siRNAs were resuspended in 1× Dharmacon RNA buffer at 0.2 to 0.28 μg/ml 
(20 μM): 1 μl of siRNA was mixed with 0.8 μg of sterile transgene in 50 μl of Optimem (Gibco). 
At the same time, 2 μl of Lipofectamine 2000 were added to 50 μl of Optimem and allowed to sit 
for 5 min. The Lipofectamine dilution was then mixed with siRNA/transgene and incubated for 
20 min at room temperature. The complete medium was removed and replaced with 0.5 ml of 
Optimem, and the mixture of siRNA/transgene and Lipofectamine was added for 4 h, after which 
time it was removed and replaced with complete medium until the slides were analyzed. 
The simian virus 40 (SV40) NLS was introduced into the enhanced green fluorescent protein 
(EGFP)-Flag-FMRP construct (75) N terminal to Flag (hereafter referred to as SV40-FMRP) (24) 
using the QuikChange XL site-directed mutagenesis kit (Stratagene) and the following primers 
from Invitrogen that were polyacrylamide gel electrophoresis purified: SV40-F,  
GACGACGATGACAAGCCAAAAAAGAAGAGAAAGGTAGAGCTGGTGGTGGAAG, and 
SV40-R, CTTCCACCACCAGCTCTACCTTTCTCTTCTTTTTTGGCTTGTCATCGTCGTC. 
The primers for the removal of the nuclear export sequence (NES), as defined in references 24 
and 31, containing amino acids 428 to 437 (QLRLERLQID) were as follows: F-
CTATTTAAAGGAAGTAGACGAGCAGTTGCGAC and R-
GTCGCAACTGCTCGTCTACTTCCTTTAAATAG. The primers for the removal of the NLS as 
defined in reference 24 containing amino acids 111 to 152 were as follows: F-
CCGAATTCGTGAGGATGATAAAGGGTGAG and R-
CCGGATCCGGTGACTTCATTGATGGA. 
An N-terminal hemagglutinin (HA) tag was introduced into the SV40-FMRP construct behind a 
T3 promoter by a two-step PCR. The constructs were cloned using the Invitrogen TA cloning kit. 
The forward primers for the addition of the HA tag followed by the addition of the T3 promoter 
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were as follows: HA, 
GCCGCCACCATGGGGTACCCATACGACGTGCCAGACTACGCTCCAAAAAAGAAGAG
AAAGGTAGAG, and T3, 
GCAATTAACCCTCACTAAAGGGAACAAAAGGCCGCCACCATGGGGTACCCATACGA
CGTGCCAGAC. The SV40-FMRP reverse primer was 
TTAGGGTACTCCATTCACCAGCGGTTCCAGCCCATCTACGCTGTC. 
 
siRNAs. 
The following siRNAs were obtained from Dharmacon (only the sense sequence will be given 
although the siRNAs were administered as a duplex): Tap/NXF1-1, 
CGAGAUCGCAUUCAUGUUAUU; Tap/NXF1-2, GCACACGCGUCUCAACGUUUU; 
Tap/NXF1-3, GGCUAUGUAUUGUAAAUGAUU; and Tap/NXF1-4, 
GCGAACGAUUUCCCAAGUUUU. The irrelevant siRNAs were derived from human FBX011, 
a putative protein arginine methyltransferase (16) that has no effect on the methylation status of 
FMRP (data not shown). 
 
Fluorescence microscopy and imaging. 
The cells were fixed with 4% (wt/vol) formaldehyde in phosphate-buffered saline (PBS; 137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.76 mM KH2PO4 [pH 7.4]) containing 4% (wt/vol) 
sucrose for 10 min at room temperature, as described previously (54). The cells were mounted in 
DAPI (4′,6-diamidino-2-phenylidole)-containing mounting medium (1× PBS [pH 9], 15% 
polyvinyl alcohol, 23% glycerol, 2% 1,4-Diaza-bicyclo[2.2.2]octane, and 1 μg/ml DAPI), 
coverslipped, and examined by fluorescence microscopy using a Zeiss Axiovert 200 M inverted 
microscope at either ×40 or ×60 magnification using oil. For immunostaining, after the fixation 
procedure described above, the cells were stained with either anti-Flag (1/1,000) (Sigma, 
St.Louis, MO) or the anti-FMRP antibody (1a) (undiluted hybridoma supernatant) for 2 to 4 h, 
washed, and then incubated with 1/800 of cy3-coupled anti-mouse antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA), mounted, and visualized as described above. 
 
Confocal microscopy and optical sectioning. 
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For live imaging by confocal microscopy, the cells were plated at 2.5 × 105 cells/ml on 35-mm 
glass-bottom microwell dishes that were poly-d-lysine-coated (MatTek Cultureware, Ashland, 
MA). The next day, they were transfected as described above. Twenty-four hours later, the cells 
were counterstained by the addition of CellTrace BODIPY TR methyl ester (Invitrogen) at a 
1/5,000 dilution and cultured for 15 min in 5% CO2 at 37°C, and the medium was replaced with 
fresh complete medium. The cells were imaged at ×63 magnification with a Zeiss LSM510 
confocal microscope using the fluorescein isothiocyanate and Cy5 settings. 
The cells prepared for fluorescence microscopy were examined by confocal microscopy using 
the Leica SP2 laser-scanning confocal with the Argon (Ar+) laser line at 488 nm for GFP and the 
785-nm line from an fs pulse Ti-sapphire laser (two-photon microscopy) for DAPI imaging. The 
cells were prepared for fluorescence microscopy and fixed in DAPI containing mounting 
medium. Optical sections of cells expressing FMRP constructs were taken using the Zeiss 
Axiovert 200 M inverted microscope with the Zeiss Apotome structured illumination system to 
increase the wide-field fluorescence contrast and for optical sectioning. 
 
RNase A treatment. 
Cos-7 cells transfected with SV40-FMRP and Tap 2 siRNA were treated with RNase A as 
described previously (67). Briefly, 36 h after transfection, the cells were preextracted in CSK 
buffer (10 mM PIPES [pH 6.8], 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2) and incubated 
on ice with CSK containing 0.05% Triton X-100 for 2 to 3 min. The cells were washed twice 
with CSK buffer before being treated with RNase A (1 mg/ml; Sigma) for 5 to 10 min and then 
washed once in CSK, fixed in 4% paraformaldehyde for 15 min, and mounted as described with 
DAPI-containing mounting medium. 
The cellular distribution of FMRP was scored for cytoplasmic or nuclear distribution by viewing 
multiple fields at ×20 magnification and counting between 100 and 200 cells with visible nuclei 
verified by the DAPI stain. The percentage of cells that expressed the EGFP-tagged FMRP 
construct (EGFP-FMRP) primarily in the nucleus was averaged from the results of three or four 
independent experiments, and the standard deviation was calculated. The numbers were analyzed 
and plotted in GraphPad Prism 4. The significance was calculated using Student's one-tailed t 
test. 
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Calculation of the ratios of total nuclear fluorescence to total cellular fluorescence. 
The consistency of scoring was evaluated by determining the ratio of total nuclear fluorescence 
to total cellular fluorescence. Using images captured at ×20 magnification, 20 representative 
cells of the three categories of cellular distribution were selected from each treatment category. 
Nuclei were demarcated by DAPI nuclear staining, and the quantification of the fluorescence 
intensity in the compartments of each cell was determined using Axiovision software. Total 
fluorescence was determined by obtaining the average fluorescence of the selection multiplied by 
the area of the selection. This value was obtained for both nuclear and whole-cell measurements. 
Total nuclear fluorescence was then divided by total cellular fluorescence to obtain the ratio of 
nuclear to total cellular fluorescence in each scoring category. A one-way analysis of variance 
was performed on each treatment group to determine whether fluorescence was significantly 
different between the analyzed cells scored as cytoplasmic, nuclear, or evenly distributed. Each 
category of cellular localization was significantly different from the other. The cells scored as 
cytoplasmic were compared to wild-type (WT) EGFP-FMRP treated with TAP-irrelevant peptide 
and were not significantly different across treatments. 
 
Antibodies and Western blotting. 
The anti-FMRP antibody 1a obtained from Jean-Louis Mandel at the Institute of Genetics in 
Illkirch, France, was used as a hybridoma supernatant for immunoblotting at a 1/10 dilution. 
Antibody reactivity was visualized using an anti-mouse horseradish-peroxidase conjugate 
(Jackson Laboratories). The rabbit anti-Tap/NXF1 antibodies (mixed 1/800 each) used for the 
experiment for which the results are depicted in Fig. Fig.22 were obtained from Genway (San 
Diego, CA) and Protein Tech Group (Chicago, IL). These antibodies were also used in Fig. 
Fig.77 for immunoprecipitation. The rabbit anti-Tap/NXF1 used for the experiment for which the 
results are depicted in Fig. Fig.6D6D was provided by Marie Louise Hammarskjold and used at 
1/1,000. The rabbit anti-Tap/NXF1 used for the experiment for which the results are depicted in 
Fig. Fig.6E6E was provided by Lyne Levesque and used at 1/1,000. The rabbit anti-FMRP K1 
antibody was provided by Andre Hoogeveen and used at a 1/2,000 dilution. The antibody against 
eIF-5 was obtained from Santa Cruz and used at a concentration of 1/10,000. Reactivity was 
visualized using an anti-rabbit horseradish-peroxidase conjugate (Amersham) and developed 
with ECL (Amersham). Quantification was performed using NIH Image. 
66 
 
Coimmunoprecipitation. 
A total of 107 Cos-7 cells/condition were plated in 150-mm dishes and transfected the following 
day with 25 μg of the indicated plasmid using Lipofectamine 2000 as per the manufacturer's 
instructions. Twenty-four hours later, the cells were harvested with trypsin and washed twice in 
PBS. The postnuclear supernatants were immunoprecipitated with the 7G1-1 antibody (12) and 
washed twice with lysis buffer and then once for 10 min with buffer containing 0.3 M NaCl-50 
mM Tris-0.5% Triton X-100 and 30 mM EDTA. The samples were split and treated with RNase 
A (60 μg Sigma) for 20 min in lysis buffer at 4°C. For the reimmunoprecipitation experiment 
and other cross-linking experiments, the transfected cells were harvested with trypsin, washed 
twice in PBS, and then treated for 10 min with 0.5% formaldehyde (Sigma) at 37°C. The cross-
linking reaction was quenched by the addition of glycine to 200 mM for 5 min at room 
temperature. The cells were washed twice in ice-cold PBS, lysed, and sonicated as described 
previously (63, 83). The postnuclear supernatants were immunoprecipitated with the 7G1-1 
antibody (12) and washed twice with lysis buffer and then once for 10 min with buffer 
containing 0.3 M NaCl/50 mM Tris/0.5% Triton X-100 and 30 mM EDTA. For the 
reimmunoprecipitation experiment, the 7G1-1 immunoprecipitations were eluted with 75 μl of 
10 mg/ml peptide—the sequence of which is described in reference 12—for 2 h at 4°C and then 
at 37°C for 10 min. The peptide elutions from the mock transfection and EGFP-FMRP 
transfections were saved and harvested for RNA as described below. The peptide elution from 
the EGFP-FMRP-Flag-Tap cotransfection was increased in volume to 0.5 ml with lysis buffer 
and reimmunoprecipitated overnight with 1 μg of anti-Tap/NXF1 antibody (Proteintech Group, 
Inc., Chicago, IL). After two washes, the cross-linking was reversed by adding sample buffer, 
incubating at 65°C for 40 min, and boiling for 5 min. All three peptide elutions were phenol-
chloroform extracted and ethanol precipitated. Isolated RNA was reverse transcribed with 
oligodeoxyribosylthymine (Invitrogen) and Superscript III (Invitrogen) following the 
manufacturer's instructions. Half of the reverse transcription reaction was amplified for the 
FMR1 mRNA, and then 1/10 of that reaction was amplified again for FMR1 mRNA. The 
forward primer for the FMR1 amplification (exons 5 to 7) was F-
CACCTCAAAGCGAGCACATA, and the reverse primer was R-
CAATAGCAGTGACCCCAGGT. 
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Oocytes, microinjection, and nuclear spreads. 
Fragments of Xenopus laevis ovary were surgically removed from adult female frogs 
anesthetized with 0.15% tricaine methanesulfonate (MS222; Sigma Chemical, St. Louis, MO). 
Stage IV to VI oocytes were manually separated using fine tweezers and maintained in saline 
buffer OR2 (82.5 mM NaCl, 2.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM Na2PO4, 5 mM 
HEPES). Glass needles were prepared using a horizontal pipette puller (P-97; Sutter Instrument 
Co.). Capped cRNA was transcribed in vitro from SpeI-linearized HA-SV40-FMRP cDNA using 
the Stratagene T3 in vitro transcription kit. RNA was isolated by phenol-chloroform extraction 
followed by ethanol precipitation. All injections were performed under a dissecting microscope 
(S; Leica) using an injector (Nanojet II; Drummond). Oocytes were injected with 20 to 30 ng of 
HA-SV40-FMRP cRNA and maintained at 18°C in OR2 solution supplemented with 100 μg/ml 
streptomycin. 
 
Chromosomal spreads. 
Nuclear spreads were prepared as described in reference 66. The samples were fixed with 2% 
paraformaldehyde in PBS plus 1 mM MgCl2 for 1 h at room temperature. After fixation, the 
nuclear spreads were rinsed in PBS and blocked with 0.5% bovine serum albumin (Sigma-
Aldrich) plus 0.5% gelatin (from cold-water fish) in PBS (blocking buffer) for 10 min. The 
immunodetection of newly made HA-tagged proteins was done using the anti-HA antibody 
mAb3F10 (Roche, Mannheim, Germany) as indicated in reference 66. 
Images were captured on an upright LeicaDMR (Heidelberg, Germany), using a PL Fluotar 40× 
oil objective (numerical aperture, 1.0), a HCL FL Fluotar 100 oil objective (numerical aperture, 
1.30), and a monochrome Retiga EXI charge-coupled device camera (Qimaging, Surrey, BC, 
Canada) driven by Invivo software (version 3.2.0; Media Cybernetics, Bethesda, MD). All 
images were captured at room temperature. 
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Chapter 3. FMRP-associated MOV10 facilitates and antagonizes microRNA-mediated 
regulation 
 
Miri Kim, Phillip J. Kenny, Radhika S. Khetani, Mary Luz Arcila, Hongjun Zhou, Kenneth S. 
Kosik, Stephanie Ceman 
This work has been submitted and in review with Molecular Cell 
3.1 Abstract 
 The fragile X mental retardation protein FMRP is an RNA binding protein that regulates 
translation of its bound mRNAs through incompletely defined mechanisms. FMRP has been 
linked to the microRNA pathway and we show here that it is associated with MOV10, a putative 
helicase that is also associated with the microRNA pathway.  We show that FMRP associates 
with MOV10 in an RNA-dependent manner and facilitates MOV10-association with RNAs in 
brain. We identified the RNA sequences recognized by MOV10 using iCLIP and found an 
increased number of G-quadruplexes in the CLIP sites. We provide evidence that MOV10 
facilitates microRNA-mediated translation regulation and also has the novel role of increasing 
the expression of a subset of RNAs by sterically hindering Argonaute2 association. In summary, 
we have identified a new mechanism for FMRP-mediated translational regulation through its 
association with MOV10.  
 
3.2 Introduction 
 Fragile X syndrome (FXS) is described as a disease of aberrant protein production [1-3]. 
As a result, FXS patients are cognitively impaired and demonstrate behavioral abnormalities that 
include autistic-like features [4]. The fragile X mental retardation protein FMRP is absent in 
FXS, establishing that FMRP is required for normal cognition. FMRP is an RNA binding protein 
that binds ~4% of brain mRNAs and regulates their expression—either enhancing or suppressing 
translation—by an unknown mechanism [5].  FMRP is implicated in microRNA (miRNA)-
mediated translational suppression [6-10], although the molecular basis for its role in this 
pathway is unknown.  
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MOV10 is a putative helicase that was initially identified in a screen of mouse embryos 
intentionally infected with the Moloney leukemia virus (MOV) [11, 12].  Like FMRP, MOV10 
has been implicated in miRNA-mediated translational suppression [13-15]. We show here that a 
subset of MOV10- and FMRP-associated mRNAs is regulated through the 3’UTR. The 3’UTR is 
the primary site of miRNA-mediated regulation where Argonaute2 (Ago2) is the key effector of 
translational suppression [16, 17]. We propose a novel mechanism of translational regulation 
whereby MOV10 binding to the 3’UTR of Ago2 regulates accessibility for subsequent 
translational regulation.   
 
3.3 Results 
FMRP associates with MOV10  
 FMRP and MOV10 are both expressed in brain and co-localized to dendritic foci by 
immunostaining [3, 13, 18].  To demonstrate their physical association biochemically, we 
prepared an RNA sedimentation gradient on brain and HEK293T cells as described [19].  FMRP 
and MOV10 were present in fractions 7-15 in brain and 7-25 in HEK293T cells (Fig 1A and 1C). 
To show that FMRP and MOV10 are in the same complex in brain, we immunoprecipitated 
FMRP from brain lysate and found it associated with MOV10 (Fig 1B). To demonstrate that 
FMRP and MOV10 directly associate in fractions from the RNA sediment gradient (versus being 
present individually in similarly sized populations), we pooled the MOV10- and FMRP-
containing fractions, immunoprecipitated FMRP and showed that MOV10 was associated with 
FMRP (Fig 1D). 
 FMRP also associates with translating ribosomes (polysomes) [20, 21].  Because we 
hypothesized that MOV10 interacts with FMRP to regulate translation, we examined its 
distribution on polysomes. FMRP and MOV10 are in the same fractions as the actively 
translating polyribosomes (Fig 1E right). Treatment with EDTA disrupts polysomes and removes 
MOV10 and FMRP from the heavier fractions, as has been described previously for FMRP [20, 
21] (Fig 1F).  
 To characterize further the interaction between MOV10 and FMRP, anti-FLAG 
immunoprecipitations were performed on murine fibroblast L-M(TK-) cells that stably expressed 
either the empty FLAG vector (VC) or FLAG-FMRP [22]. MOV10 specifically associated with 
FMRP and this association was disrupted in 300 mM NaCl and was partially disrupted by 
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treatment with RNase A (Fig 1G). In the reverse experiment, immunoprecipitation of myc-
tagged MOV10 demonstrated that endogenous FMRP co-immunoprecipitated in an RNA-
dependent manner (Fig 1H).  We conclude that FMRP association with MOV10 is RNA-
dependent.  
 
Identification of the cellular RNAs bound by MOV10  
 Because FMRP and MOV10 associated in an RNA-dependent manner, we next sought to 
identify the mRNAs associated with MOV10.  RNAs associated with FMRP in brain and cell 
lines have been extensively characterized [5, 23-25]. To identify the RNAs that bound MOV10, 
we UV-cross-linked HEK293F cells and immunoprecipitated with an irrelevant antibody (ir) 
followed by a MOV10-specific antibody (MOV10) to isolate associated RNAs after stringent 
washing. We then prepared a library and a biological replicate for deep sequencing (Fig 2A, 
right). The top 20 RNAs associated with MOV10 are shown in the table in Figure 2B (the entire 
list is shown in Table S1). To identify the specific region of the RNA bound by MOV10, we 
performed individual-nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP) 
as described [26, 27].  Radiolabeled RNA bound to MOV10 was visualized at ~135 kDa (Fig 
2A, left) cut-out, along with a similarly sized region from the irrelevant immunoprecipitation as a 
control. 1,181 regions were found in both CLIP libraries at least twice: 1036 of these 
corresponded to regions identified as 3’UTRs, exons, introns and 5’UTRs (Table S2). This 
stringent number provided the most confidence that the RNAs identified were true MOV10 
targets. Importantly, 90% of the annotated MOV10 CLIP targets were identified in the RNA IP 
(Figure 2A right, Figure 2B and Table S1).  
 Once the MOV10 CLIP sites were normalized to the length of each gene region, the 
3'UTR was determined to be the primary MOV10 binding site (Figure 2C). We were interested 
in determining whether MOV10 regulated specific molecular functions. Gene Ontology (GO) 
analysis of the MOV10 CLIP targets showed a clear enrichment (p≤0.05) for certain categories 
of molecular function (Figure 2D). The MOV10 3’UTR CLIP RNAs were significantly enriched 
for nucleotide binding proteins, RNA binding proteins, and transcription factors compared to the 
MOV10 exon CLIP RNAs, which were enriched for RNAs encoding proteins with a ligase 
activity.  
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FMRP recruits MOV10 to target mRNAs in the brain  
 Because we found MOV10 and FMRP associated in an RNA-dependent manner, we 
wanted to identify the commonly bound RNAs. Accordingly, we compared previously published 
FMRP CLIP targets with our MOV10 CLIP sites and found a large number of overlapping 
mRNAs (Figure 3A).  We examined the CLIP lists of FMRP isolated from HEK293 [23] and 
from brain polyribosomes [24] and found 69.5% overlap between the MOV10 CLIP targets and 
HEK293 FMRP CLIP targets and 23.6% overlap between the MOV10 CLIP targets and brain 
FMRP CLIP targets (Figure 3A and Table S3 for a complete list).  
 Since FMRP and MOV10 bind some of the same mRNAs, we hypothesized that FMRP 
binds the mRNA first and then recruits MOV10 for subsequent binding and translational 
regulation. We chose to address this question in brain because both FMRP and MOV10 are 
expressed in neurons [3, 13, 18]. To test this hypothesis and validate specific mRNAs found by 
deep sequencing, we selected three mRNA targets (GNB2L1, CALM3, and eEF2) that were 
identified independently using both strategies shown in Figure 2A.  Importantly, CALM3 and 
eEF2 were also present in the FMRP brain CLIP list while GNB2L1 was not present in the 
FMRP CLIP list [24].  Thus, CALM3 and eEF2 associate with both FMRP and MOV10 while 
GNB2L1 only associated with MOV10. To examine whether FMRP facilitated association of 
MOV10 with RNAs in brain, we immunoprecipitated MOV10 from both WT and FMR1 
knockout brains and quantified the associated RNAs. MOV10 association with eEF2 and 
CALM3 was significantly reduced in the absence of FMRP (Figure 3B) suggesting that FMRP 
was required for efficient loading of MOV10 onto its mRNAs.  As expected, because GNB2L1 
does not associate with FMRP, MOV10 bound equally well to GNB2L1 in both the presence and 
absence of FMRP in brain (Figure 3B). It is important to note that the levels of all three RNAs 
were the same in brains of both WT and FMR1 knockout (KO) mice (Figure 3C). Thus, FMRP is 
required for normal association of a subset of RNAs with MOV10, suggesting that FMRP binds 
a subset of mRNAs and recruits MOV10 to those RNAs. 
 
FMRP and MOV10 recognize GQ structures 
 We next hypothesized that there were specific motifs or secondary structures in the RNA 
targets that were recognized by MOV10. The motifs recognized by FMRP have been extensively 
characterized [5, 23, 28, 29] and include G-quadruplexes (GQs) [30].  GQs are nucleic acid 
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structures formed by square coplanar arrays of four guanines (G-quartets) that are stabilized by 
Hoogsteen-type hydrogen bonds [31, 32].  Two or more G-quartets stack to form a GQ [33].  
RNA GQs can be substrates for helicases, as is the case for G4R1/RHAU and DHX9—helicases 
that are primarily nuclear [34, 35].  
 GQs are found in a large number of RNAs [36, 37]. To examine the MOV10 CLIP sites 
for putative GQs, we used a GQ prediction program QGRS [37, 38] and found that 27.2% of the 
MOV10 3’UTR CLIP sites contained predicted GQs--nearly twice that predicted in a large-scale 
screen of 3’UTRs [36].  Accordingly, QGRS identified several putative GQs or clusters of GQs 
within or in proximity to the identified MOV10 binding sites in eEF2, CALM3, and GNB2L1 
(Figure 3D). To ask directly whether MOV10 bound GQs, we tested its ability to bind the RNA 
sc1, which is a model GQ that binds FMRP with nanomolar affinity [28]. Like FMRP, MOV10 
was able to specifically bind sc1 and was unable to bind the nucleotide-substituted sc1-mutant, in 
which formation of the GQ is disrupted (Fig 3E).  Thus, both FMRP and MOV10 bind GQ 
structures.  
 
MOV10 regulates mRNA expression through the 3’UTR and modulates Ago2 function. 
 MOV10 bound most CLIP targets in the 3’UTR (Fig 2C). Previous work demonstrated 
that MOV10 co-immunoprecipitated with Ago2 and was required for silencing of a reporter 
RNA [14, 39]. If MOV10 is indeed participating in miRNA-mediated silencing, then some of its 
target mRNAs should be degraded as a consequence of miRNA-mediated translation suppression 
[40-42].  Accordingly, knockdown of MOV10 should lead to an increase in expression of those 
same mRNAs.  
 To examine the effect of MOV10 on total mRNA levels, we treated HEK293F cells with 
MOV10 siRNAs for knockdown (KD), irrelevant siRNAs as a control (IR), or we overexpressed 
a MOV10 transgene (OE) and evaluated mRNA levels under each of these treatment conditions 
by RNA-Seq (Table S4). We identified 14,679 RNAs in the total RNA pool, and found that 6057 
RNA levels changed significantly in the KD while 7593 targets changed in the OE.  The changes 
in RNA levels in both the KD and OE were significant (p<0.05) compared to control treatment 
(Fig 4A). There were 3313 genes that showed significantly changed RNA expression in both 
treatment conditions.  Of the genes in the intersection, 1216 RNAs changed in opposite 
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directions in the KD or OE of MOV10: more specifically, in the absence of MOV10, 604 RNAs 
increased while 612 decreased. In the OE, those same RNAs changed in the opposite direction. 
Many of these significantly changed RNAs are likely downstream of MOV10, rather than being 
directly bound and regulated by MOV10. In fact, the GO analysis indicated that transcription 
factors were directly regulated by MOV10 (Figure 2B). Thus, genes that are downstream targets 
of those transcription factors were likely affected in the KD and OE experiments. To focus on 
the fate of the RNAs that are directly bound by MOV10--as identified by iCLIP--we compared 
the fate of the MOV10 CLIP targets to the non-CLIP targets in Figure 4B.  As would be 
expected, direct binding by MOV10 had a significant impact on the levels of mRNAs.  The 
MOV10 CLIP targets were changed significantly in the KD (p=0.0068) and the OE (p=1.833E-
26) experiment (Figure 4B and Table S5). The larger effect observed in the OE experiment likely 
reflects the fact that the MOV10 transgene was overexpressed (>30-fold [data not shown]). Thus, 
RNAs that are directly bound by MOV10 are more likely to have significantly altered expression 
levels in the absence of MOV10 or when MOV10 is overexpressed, than the RNAs that are not 
CLIP targets. 
 We next visualized the direction of change of the MOV10 CLIP targets by heat map (Fig 
4C). The significantly changed MOV10 CLIP targets in KD, IR, and OE clustered in a very 
distinct manner, correlating with their treatment (Fig 4C). If MOV10 participates in miRNA-
mediated silencing, as has been hypothesized [14, 15], then MOV10 KD would be predicted to 
lead to increased levels of its CLIP targets (red in Figure 4C) and decreased levels upon MOV10 
OE (blue in Figure 4C), which occurred in the RNA cluster indicated by the yellow bar on the 
left.  Importantly, there were also clusters of RNAs that demonstrated the opposite expression 
pattern: MOV10 KD resulted in decreased expression (blue) and MOV10 OE resulted in 
increased expression (red). These RNA clusters are indicated by orange and lime green bars in 
Figure 4C. These two patterns of expression suggest that MOV10 binding to target RNAs had 
two distinct fates: MOV10 increased the RNA levels of some CLIP targets and decreased the 
RNA levels of other CLIP targets.  
 Because of the hypothesized role of MOV10 in the microRNA pathway and the greater 
efficacy of miRNA silencing response elements in the 3’UTR [17, 43], we were particularly 
interested in the fate of the mRNAs in which MOV10 bound the 3’UTR. We examined the effect 
of MOV10 OE on non-CLIP RNAs and found that of the RNAs that were significantly changed, 
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25.05% decreased in expression and 26.9% increased in expression (Figure 4D left).  In contrast, 
when examining MOV10 OE on RNAs that are 3’UTR CLIP targets, 47.2% were significantly 
decreased and 15.8% were increased (Figure 4D, center). The larger percentage of 
downregulated RNAs among the 3’UTR CLIP targets (47.2%) compared to the non-CLIP RNAs 
(25.05%), is consistent with a role for MOV10 in miRNA-mediated regulation and degradation, 
where increased levels of MOV10 drove decreases in target RNA levels. Examination of the 
intronic CLIP targets (presumably bound by MOV10 in the nucleus) revealed a fate more similar 
to that observed for the non-CLIP RNA (Figure 4D right). Thus, MOV10 OE leads to 
significantly decreased levels of the 3’UTR CLIP targets, supporting a role for MOV10 in 
microRNA-mediated translational suppression, accompanied by mRNA degradation.  
Because direct binding of MOV10 to RNAs had a distinct effect on mRNA fate as shown in 
Figure 4B and 4C, we analyzed the 3’UTR CLIP targets for the presence of Ago2 CLIP sites 
[44], exploring the hypothesis that MOV10 binding modulates miRNA-mediated translation 
suppression by either facilitating or blocking Ago2 association. Of the Ago2-bound regions 
identified [44], 532 were overlapped with the 1,181 regions identified in the MOV10 CLIP 
libraries, supporting the hypothesis that MOV10 participates in miRNA-mediated translation 
regulation.  
 We observed three categories of RNAs with 3’UTR MOV10 CLIP sites: 1) RNAs with 
overlapping MOV10 and Ago2 CLIP sites (Figure 4E, left); 2) RNAs with MOV10 and Ago2 
CLIP sites that did not overlap (Figure 4E, middle); 3) RNAs that contained no Ago2 CLIP sites 
in their 3’UTR (Figure 4E, right). When the MOV10 CLIP sites overlapped with the Ago2 CLIP 
sites, the percentage of RNAs that decreased upon MOV10 KD was significantly larger than the 
percentage of RNAs that decreased when there were no Ago2 CLIP sites (36% compared to 
21.7%, p=0.042). This observation suggested a protective role for MOV10 on those RNAs where 
the MOV10 binding site overlaps with the Ago2 binding site such that loss of MOV10 led to 
decreased RNAs. Accordingly, the percentage of RNAs that increased upon MOV10 knockdown 
when the MOV10 and Ago2 sites overlapped was significantly reduced compared to the 
percentages of increased RNAs in the other two categories (10% compared to 26.% and 29.6%, 
p<0.05).  Thus, when the MOV10 and Ago2 CLIP sites overlap, MOV10 binding antagonizes 
Ago2-mediated transcript reduction. 
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 To evaluate the fate of MOV10 on steady-state protein levels encoded by individual 
CLIP targets, we examined the 3’UTR MOV10 CLIP targets whose RNAs were previously 
shown to be regulated by miRNAs in HEK293 cells [45]. MOV10 knockdown significantly 
increased the expression of endogenous Phactr2, TGFB1 and SAMHD1 (Figure 5A), as would 
be expected if MOV10 facilitated miRNA-mediated suppression.  This translational regulation 
occurred through their respective 3’UTRs (Figure 5B).  Thus, MOV10 facilitated miRNA-
mediated translation suppression of the proteins encoded by these 3’UTR CLIP targets. 
In contrast, endogenous protein levels of MAZ were decreased upon MOV10 KD (Figure 5A), 
suggesting that MOV10 functions to enhance MAZ expression. The effect of MOV10 on MAZ 
was localized to the 3’UTR based on luciferase reporter expression (Figure 5B). The dependence 
of MAZ on MOV10 was similar to those RNAs that decreased in the absence of MOV10 (Figure 
4B, 4C and 4E), suggesting that MOV10 normally upregulates the mRNA and protein levels of a 
subset of CLIP targets.  
 In Figure 5C we show the spatial arrangement of the MOV10 CLIP sites, the Ago2 CLIP 
sites and the putative GQs in the 3’UTRs of the proteins on which MOV10 had opposing effects: 
MAZ, whose expression is enhanced by MOV10, and Phactr2 and SAMHD1—the expressions 
of which are suppressed by MOV10. We propose that when MOV10 binding occurs at Ago2 
sites--perhaps facilitated through an increased density of GQs--Ago2 binding and consequently, 
miRNA-mediated silencing, is blocked and RNA and protein levels increase, as in the case for 
MAZ.  In contrast, when MOV10 binding occurs near (but not coincident with) Ago2 sites, Ago2 
binding is enhanced and miRNA-mediated silencing proceeds, resulting in decreased RNA and 
protein levels, as is the case for Phactr2 and SAMHD1. These results demonstrate that proximity 
of Ago2 and MOV10 binding sites is important for the regulatory effects of MOV10 on target 
mRNAs.  More broadly, since FMRP recruits MOV10 to a subset of RNAs, this suggests that 
association with MOV10 is a new mechanism for FMRP-mediated translation regulation (Figure 
5D).  
 
3.4 Discussion 
 FMRP regulates the translation of its bound mRNAs--either activating or suppressing 
translation [5]; however, the mechanism of regulation is largely unknown, with a few exceptions 
[46, 47].  miRNAs are a potent mechanism for translational regulation and both FMRP and 
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MOV10 are implicated in the miRNA pathway [14, 39, 48, 49]. Recently, MOV10 was shown to 
participate in translational suppression of mRNAs important for neuronal development and 
function [13]. Here, we demonstrate that MOV10 does indeed influence mRNA levels and 
subsequently translation, through the 3’UTR, supporting a role for MOV10 in miRNA-mediated 
regulation. In addition to facilitating Ago2 association, which has previously been suggested [15, 
39], MOV10 binding also blocks miRNA-mediated translation suppression and consequently 
mRNA degradation by interfering with Ago2 binding sites, similar to the novel function recently 
described for polypyrimidine tract binding protein PTB [44]. PTB suppressed or enhanced 
miRNA targeting by competitive binding on target mRNAs or altering local RNA secondary 
structure [44].  Like PTB, MOV10 joins the growing list of RNA binding proteins including 
HuR, Dnd1, CRD-BP and PUM1 that have been implicated in modulating miRNA targeting 
[50]. 
 MOV10 demonstrates specificity for secondary structure, namely GQs, as determined 
through bioinformatic analysis of CLIP targets and an RNA capture assay using a known GQ, 
sc1. GQ structures create the highest thermodynamically stable structure per base pair found in 
nucleic acids, and have been reported to play important roles in translational regulation, acting in 
both the 5’UTR and the 3’UTR [35].  In fact, the 3’UTR of PSD-95—an FMRP target--also 
contains three GQ forming sequences, one of which contains a functional miRNA binding site 
[10].  
 At this point, we do not know if the GQ functions only to bind MOV10 and change the 
local environment of the RNA or if the GQ is also subsequently unwound by MOV10, as 
MOV10 is a putative helicase [11, 12].  Notably, there are 3’UTR CLIP targets where the 
MOV10 CLIP site overlapped with the Ago2 site and the mRNAs increased in the absence of 
MOV10, suggesting that MOV10 facilitated miRNA-mediated translational suppression of those 
RNAs—a fate opposite to that of MAZ. Significantly, in those RNAs, the MOV10 CLIP sites did 
not contain GQs, suggesting that MOV10 bound nearby to facilitate Ago2 mediated-suppression, 
which is what we suspect is occurring for SAMHD1 and Phactr2. Another important issue to 
consider may be the strength or stability of the GQ, which may determine the ultimate fate of 
MOV10 on the mRNA it binds.  
  While we explored the role of MOV10 binding and regulation in the 3’UTR, we 
observed that 36.9% of the MOV10 CLIP targets in the 3’UTR showed no change in RNA levels 
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upon either depletion or overexpression of MOV10 (Figure 4D, middle). This lack of an effect 
on mRNA levels is suggestive of other roles for MOV10 outside of the miRNA pathway. In fact, 
a recent study showed that MOV10 played a role in an Ago-independent mechanism of LINE 
RNA degradation [51].  MOV10 also has a nuclear role, participating in transcriptional silencing 
[52] and associating with spliceosomes [[53] Table S2], which could explain its binding to 
introns. In that study, MOV10 is named functional spliceosome-associated protein 113 
(fSAP113). Finally, MOV10 has been demonstrated to play an important role in viral pathways, 
influencing the replication and infectivity of HIV and HDV [54, 55].  
 In summary, we have identified a novel functional partner for FMRP that modulates 
miRNA-mediated translation regulation by Ago2, giving insight into how FMRP regulates 
translation of a subset of its bound RNAs. 
 
3.5 Experimental Procedures 
 
Immunoprecipitations, immunoblotting, RNA capture assays and gradients. 
Immunoprecipitating antibodies:  anti-FMRP 7G1-1 [5] and anti-MOV10 (Bethyl), agarose 
conjugated anti-Myc (Sigma), irrelevant antibody (rabbit antibody specific for Zebra finch 
FMRP [56]). Immunoprecipitations and immunoblots were performed as previously described 
[57]. Additional antibodies used for immunoblot include anti-FMRP [58]), anti-FMRP (Abcam 
ab17722), anti-Phactr2 (Abcam ab85262), anti-MAZ (Santa Cruz sc-28745) anti SAMHD1 
(Thermo Scientific PA5-27898) anti TGFb1 (Sigma AV37156-100UG), anti-eIF5 (Abcam), 
HRP-conjugated anti-rabbit and anti-mouse antibodies (Jackson Laboratories). RNA capture 
assays with sc1 and sc1 mutant were performed as described [59] Myc-MOV10 was transiently 
transfected into HEK293F cells and immunoprecipitated using anti-Myc conjugated beads 
(Sigma) and eluted with Myc peptide. 15-45% Polysome gradients were performed as described 
in [60].  15-30% sucrose gradients were performed as described in [19]. Protein was isolated 
from 100-500 uL fractions using TCA.   
 
RNA isolation and qRT-PCR  
Total RNA was isolated from adult male mouse brains (WT FVB.129, FVB FMR1 knockout 
mice, or C57/BL6) and treated HEK293F cell lines using Trizol (Life Technology) following 
84 
 
manufacturer’s instructions, treated with DNase I (Biolabs) and Phenol:chloroform extracted.  
qRT-PCR was performed with iQ SYBR Green supermix and run on a StepOnePlus RT PCR 
machine (Biosystems) in triplicate. Statistical analysis was performed using a Student’s t-Test. 
The statistics for the RNA-seq analysis is described in the Supplemental Methods. See Table S6 
for the list of PCR primers.  
 
Transfections and Luciferase assays 
HEK293T or HEK293F cells were transfected with irrelevant or MOV10 specific siRNAs 
(Dharmacon) using PEI (Sigma) for 6 hrs.  24 hrs later, a second transfection containing 
irrelevant or MOV10 specific siRNA, 900 ng eGFP, 100 ng Psicheck luciferase reporter was 
performed.  500 ng TGFB1 in PGL3 was transfected with 500  ng eGFP, and 10 ng renilla 24 hrs 
post MOV10 knockdown.  Luciferase activity was measured using a dual-luciferase reporter 
assay kit (Promega) on a SynergyTM HT Multi-detection plate reader 24 hours post secondary 
transfection. 
 
MOV10-RNA coIP  
HEK293F cells were UV-cross-linked three times (Stratalinker), lysed in 0.3 M lysis buffer (50 
mM Tris 7.5, 300 mM NaCl, 30 mM EDTA, 0.5% triton). Lysate was cleared by 
ultracentrifugation at 30K for 35 min and precleared with irrelevant antibody followed by 
MOV10 specific antibody. IP was treated with DNase followed by RNase and subsequent 
washing in high salt buffer followed by proteinase K treatment. RNA was eluted and isolated by 
phenol/chloroform extraction followed by ethanol precipitation.  Library preparation and 
sequencing analysis was performed using reagents for SOLiD sequencing on a SOLiD 4.0.  
 
iCLIP 
A published iCLIP protocol was followed [26, 27] with the following exceptions: phosphatase 
treatment was performed using shrimp alkaline phosphatase (SAP), the irrelevant 
immunoprecipitation was performed with a rabbit affinity purified antibody to zebra finch 
FMRP, described in [56]. MOV10-CLIP libraries were sequenced by the UIUC sequencing core 
facility using the Illumina HiSeq2000 platform.  Sequences were trimmed and evaluated for 
quality and aligned to human genome hg19 (see Supplemental Experimental Procedures). 
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RNA-Seq analysis 
Raw FASTQ data was quality-trimmed from the 3’ end using the program Trimmomatic (v 0.22; 
Lohse et al. 2012), using a minimal PHRED quality score of 20 and a minimal length of 30.  
Sequences were then aligned using TopHat v. 2.0.8 [61] and Bowtie 2.1.0 [62] as described in 
Supplemental experimental procedures.   
The genome sequence index was hg19 from UCSC 
(http://hgdownload.soe.ucsc.edu/downloads.html#human).  The raw read counts were input into 
R 3.0.0 [63]a for data pre-processing and statistical analysis using packages from Biocondutor 
[64] and analyzed as described in the supplemental experimental procedures.  
Accession Numbers:  All iCLIP data files and RNA-Seq files will be available for download 
from NCBI Omnibus (http://www.ncbi.nlm.gov/geo/) under an accession number yet to be 
assigned because the submission in in process.  
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3.6 Figures 
 
Figure 3.1. FMRP associates with MOV10 in brain and cell lines. a) Mouse brain extracts 
were analyzed by sucrose gradient centrifugation [19]. Odd numbered fractions (1-lightest-25-
heaviest) were immunoblotted (ib) for FMRP and MOV10. b) FMRP was immunoprecipitated 
(IP) from whole brain lysate and immunoblotted for MOV10. c) HEK293F extracts were 
analyzed by sucrose gradient centrifugation as in A).  d) Fractions containing both FMRP and 
MOV10 were pooled and immunoprecipiated for FMRP and immunoblotted for MOV10. e) 
HEK293T cells were fractionated on a sucrose gradient for polyribosome analysis: positions of 
the 40S and 60S subunits, the 80S ribosomes and mRNAs with multiple ribosomes (polysomes) 
are indicated. Fractions were immunoblotted for MOV10 and FMRP. f) EDTA treatment was 
used to disrupt polyribosomes, as described [20]. The small spike between fractions 7 and 8 is a 
technical artifact. g) FLAG-FMRP was immunoprecipitated from L-M(TK-) cells expressing the 
empty FLAG vector (VC) or stably expressing FLAG-FMRP (F-FMRP) [22] in the presence of 
high EDTA to disrupt polyribosomes, treated with RNase A (+) or not (-) and 150 mM or 300 
+- +-+-
-- +++-
++ --++
80s
60s
40s
++ ---+ --
-- +++- ++
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mM NaCl, as described [22] and immunoblotted (ib)  for MOV10 or FLAG (left). h) HEK293T 
cells were transfected with myc-tagged MOV10, immunoprecipitated for myc-tag, treated with 
RNase A and immunoblotted for endogenous FMRP [58] and myc. 
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Figure 3.2. MOV10 binds a subset of mRNAs. a) Schematic of library preparations for 
MOV10 cross-linked immunoprecipitations (right) and CLIP (left).  Right, silver stain of UV-
cross-linked immunoprecipitations (IP), MOV10 (arrow); Left, autoradiography of [
32
P]-labeled 
MOV10-RNA complex (star), C7 iCLIP library. Ir-irrelevant immunoprecipitation, Ig-
immunoprecipitating antibody alone. b) Top 20 RNA targets in the UV-cross linked MOV10 IP.  
c) Distribution of MOV10 CLIP binding sites identified in both C5 and C7 libraries plotted as 
reads per kilobase per million reads.  d) GO analysis of MOV10 CLIP targets based on region 
bound.  Significance (p<0.05) is indicated by the black line. 
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Figure 3.3.  MOV10 recognizes a subset of RNAs bound by FMRP and GQs. a) Venn 
diagram showing overlap of MOV10 CLIP targets with previously published FMRP CLIP RNAs 
isolated from brain (Darnell et al., 2011) and FMRP isoform 1 CLIP RNAs isolated from 
transfected HEK293 cells (Ascano et al., 2012). b) Real-time PCR quantification of MOV10-
associated RNAs (eEF2, CALM3 and GNB2L1) immunoprecipitated from WT and FMR1 
knockout (ko) brains (n=3). c) Real-time PCR quantification of indicated RNAs from WT and 
FMR1 knockout brains (n=3). d) Schematic showing predicted GQs (pink bars) in CALM3, 
eEF2, and GNB2L1 (UTRs are thin lines; coding sequence is thick line) and MOV10 clip sites 
(green bars).  e)  Immunoblots (ib) of in vitro synthesized FMRP and purified recombinant 
MOV10 in RNA capture assays using the GQ sc1 and sc1 mutant (RNAs shown by ethidium 
stain of an agarose gel). 
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Figures 3.4.  MOV10 affects mRNA levels of CLIP targets. a) Venn diagram of significantly 
changed RNAs (p<0.05) in MOV10 knockdown (KD) (6057 RNAs) or overexpression (OE) 
experiments (7593 RNAs). 3313 RNAs were common to both treatments. b) CLIP targets in the 
MOV10 knockdown (KD) were significantly changed compared to the non CLIP RNA under 
knockdown conditions (non-CLIP) (left, p=0.0068); CLIP targets in the MOV10 overexpression 
(OE) were significantly changed (CLIP) compared to the non-CLIP RNA (right, p=1.83E-26). c) 
Heatmap of significantly changed CLIP RNAs in MOV10 knockdown (KD), irrelevant siRNA 
(IR), and transgene overexpression (OE) experiments. Colored bars indicate discrete clusters of 
RNAs. Individual experiments are indicated on the top. d) Distribution of RNAs in MOV10 
overexpression experiments that did not change (blue), significantly decreased (green) or 
significantly increased (yellow) for total RNA (left), for RNAs containing 3’UTR CLIP targets 
(center) or RNAs containing intronic CLIP targets (right).  e) Distribution of RNAs in MOV10 
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knockdown experiments that did not change (blue), significantly decreased (green) or 
significantly increased (yellow) that had overlapping MOV10 and Ago2 CLIP sites in the 3’ 
UTR (left, 50 RNAs), non-overlapping MOV10 and Ago2 CLIP sites in the 3’UTR (center, 167 
RNAs) or no Ago2 CLIP sites in the 3’UTR (right, 115 RNAs). Decreased: 36% vs. 22% is 
significant (X
2
= 2.9752, df = 1, p-value = 0.04228) (1-tailed).  Increased: 10% vs. 26% = X2 = 
4.9842, df = 1, p-value = 0.01279 (1-tailed); 10% vs. 30% = X2 = 6.3465, df = 1, p-value = 
0.005881 (1-tailed). 
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Figure 3.5. Effect of MOV10 on miRNA-regulated protein expression. a)  Immunoblots (ib) 
for indicated endogenous proteins in HEK293T cells treated with irrelevant siRNAs (Irrel) or 
MOV10 siRNAs. eIF5 is a loading control. Right, fold-change of proteins in three independent 
experiments, * p<0.05, ** p<0.01 (right).  b) 3’UTRs of MAZ, SAMHD1 and TGFB1 were 
subcloned into luciferase reporter plasmids and the effect of MOV10 loss examined. * p<0.05, 
** p<0.01. c) 3’UTRs of MAZ, Phactr2 and SAMHD1, showing the relationship between GQs 
(pink bars), MOV10 CLIP sites (green bars), and Ago2 CLIP sites (blue bars).  d) Model for 
FMRP-associated, MOV10-mediated translation regulation. FMRP binds mRNAs and recruits 
MOV10 to GQs. MOV10 binding facilitates the availability of nearby miRNA binding site (red) 
for Ago2-mediated translation suppression/RNA degradation through bound miRNA (blue) 
(left). If the miRNA binding site is within the GQ, MOV10 binding precludes Ago2 association, 
leading to an increase in stability of the RNA and subsequent translation (right). 
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3.7 Supplemental Methods and Tables 
Supplementary Files 
Supplemental figures and legends, tables, Experimental Procedures, and references (in this order). 
Table S1, related to Figure 3.2 .  SOLiD sequencing platform results 
Table S2, related to Figure 3.2. Identified MOV10 CLIP sites.   
Table S3, related to Figure 3.3.  Overlapping targets with Darnell and Ascanano CLIP lists 
Table S4, related to Figure 3.4. Results of RNA seq analysis 
Table S5, related to Figure 3.4.  Significantly changed mRNA targets from RNA seq analysis.  
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Table S4 
 
Table S4.  Total RNA seq analysis of MOV10 knockdown, overexpression, or irrelevant siRNA 
treatment.   
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Supplemental Experimental Procedures.   
Transfectons and total RNA isolation and RT-PCR 
HEK293T cells were transfected with irrelevant or MOV10 specific siRNAs (Dharmacon), or 
myc-MOV10 using PEI (Sigma) for 6 hours.  siRNA transfections were performed at 24 hr 
intervals for 72 hours.  Myc-MOV10 overexpression transfection was performed once and 
harvested 48 hrs later.  Cells were lysed and RNA was isolated using Trizol (Life Technology) 
following manufacturer’s instructions, treated with DNase I (Biolabs) and Phenol:chloroform 
extracted.  qRT-PCR was performed with iQ SYBR Green supermix and run on a StepOnePlus 
RT PCR machine (Biosystems) in triplicate. Statistical analysis was performed using a Student’s 
t-Test. 
Primers used for RT-PCR: 
 
Comparison of RNA lists 
VLookup was used to compare FMRP CLIP lists from FMRP iso1 (ascano) and polysomal 
FMRP (darnell) 
 
RNA-Seq analysis 
Raw FASTQ data was quality-trimmed from the 3’ end using the program Trimmomatic (v 0.22; 
Lohse et al. 2012), using a minimal PHRED quality score of 20 and a minimal length of 30.  
Sequences were then aligned using TopHat v. 2.0.8 [61] and Bowtie 2.1.0 [62] using the 
following parameters: 
tophat2 --coverage-search -p 8 -N 7 --read-edit-dist 7 --library-type fr-firststrand -o 
<SAMPLE_NAME> <REFERENCE_DATABASE>  <TRIMMED_FASTQ> 
Name Sequence (5' to 3')
CALM3 F CTTCGACAAGGATGGAGATGG
CALM3 R AACTCTGGGAAGTCAATGGTC
Eef2 F ACATTCTCACCGACATCACC
Eef2 R GAACATCAAACCGCACACC
GNB2L1 F AATACTGTGGGTGTCTGCAAG
GNB2L1 R TTAGCCAGATTCCACACCTTG
GAPDH F CTTTGTCAAGCTCATTTCCT
GAPDH R CTTGCTCAGTGTCCTTGC
MAZ F GCCGCTCGAGGTGATCCGTGGTGTTTCTCCTG
MAZ R CATCAGCAAGGCGGCCGCGGCAGTTCTTAGTGAGGGCAA
SAMHD1 F GCCGCTCGAGTGGGTGGTCCTAATTTCAGCA
SAMHD1 R CATCAGCAAGGCGGCGCCAAAATCCAACTCGCCTCCG
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The genome sequence index (<REFERENCE_DATABASE>) was hg19 from UCSC 
(http://hgdownload.soe.ucsc.edu/downloads.html#human).  The BAM alignments were first 
changed to SAM format using samtools (v 0.1.18, Li et al. 2009) and then raw read counts were 
tabulated for each sample at the gene level using the GTF gene model file <GTF_FILE> for 
hg19 from UCSC and htseq-count, from HTSeq v0.5.3p9 (http://www-
huber.embl.de/users/anders/HTSeq/doc/index.html) using the default "exon" feature type,  
"gene_id" attribute and the following parameters: 
htseq-count -s reverse -m intersection-nonempty - <GTF_FILE>  
The raw read counts were input into R 3.0.0 [63]a for data pre-processing and statistical analysis 
using packages from Biocondutor [64] as indicated below. Initial quality control analysis 
indicated that one of the three KD replicates was an outlier and it was removed from the analysis. 
Genes without 1 Count Per Million (CPM) mapped reads in at least one of the 8 samples were 
filtered out due to unreliable data in any sample; 14,615 of the 23,368 genes passed this filter and 
were analyzed using edgeR 3.2.1 [65]. The raw count values were used in a negative bionomial 
statistical model that accounted for the total library size for each sample and an extra TMM 
normalization factor [66] for any biases due to changes in total RNA composition of the samples. 
Pairwise comparison for KD vs. IR and OE vs. IR were pulled from the model and separately 
adjusted for multiple testing using the False Discovery Rate method [67]; genes with FDR p < 
0.05 were considered significantly different.  For sample clustering and heatmaps, comparable 
expression values were generated from the read counts using edgeR's modified log2 CPM 
values. Additional annotation information (gene names, descriptions, Gene Ontology terms and 
pathways) was obtained from Bioconductor's org.Hs.eg.db package (v. 2.9.0; based on NCBI's 
Entrez database) using the transcript IDs provided in the GTF gene model file instead of the gene 
symbols. To compare with the CLIP data, the genomic regions showing CLIP targets for 
MOV10 were annotated to the closest gene using gene symbols for hg19 from Ensembl and 
assigned to a region of the gene (e.g., 3' UTR, exon, intron, etc.). Due to discrepancies between 
gene symbols from UCSC, NCBI and Ensembl, and multiple gene symbols for some CLIP 
targets, only 947 of the original 1049 CLIP targets could be matched to genes from the RNA-Seq 
data. This represented 779 different genes, as some genes had CLIP targets in more than one 
region and/or multiple CLIP targets within a region. Not counting multiple targets per region but 
allowing more than one region per gene, there were 360 genes with CLIP targets in the 3' UTR, 
269 genes with CLIP targets in exons and 163 genes with CLIP targets in introns.  For the KD 
vs. IR and OE vs. IR comparisons, the number of significantly up-regulated, down-regulated and 
non-significant genes among the 779 genes with CLIP targets were compared with the rest of the 
13,863 genes using a Pearson's chi-squared test. Within each region, a similar comparison 
between the numbers of up, down and no-change genes with CLIP targets versus the rest of the 
genes without targets in that region was done with separate Pearson's chi-squared tests for each 
region. 
MOV10-RNA coIP and iCLIP 
HEK293F cells were UV-cross linked three times (Stratalinker), lysed in 0.3 M lysis buffer (50 
mM Tris 7.5, 300 mM NaCl, 30 mM EDTA, 0.5% triton). Lysate was cleared by 
ultracentrifugation at 30K for 35 min and precleared with irrelevant antibody followed by 
MOV10 specific antibody. IP was treated with DNase followed by RNase and subsequent 
washing in high salt buffer followed by proteinase K treatment. RNA was eluted and isolated by 
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phenol/chloroform extraction followed by ethanol precipitation.  Library preparation and 
sequencing analysis was performed using reagents for SOLiD sequencing on a SOLiD 4.0. 
iCLIP: A published iCLIP protocol was followed [26, 27] with the following exceptions: 
phosphatase treatment was performed using shrimp alkaline phosphatase (SAP), the irrelevant 
immunoprecipitation was performed with a rabbit affinity purified antibody to zebra finch 
FMRP, described in [56]. MOV10-CLIP libraries were sequenced by the UIUC sequencing core 
facility using the Illumina HiSeq2000 platform.  Sequences were trimmed and evaluated for 
quality and aligned to human genome hg19 
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Chapter 4. Single molecule studies of transcribed RNA 
 
 
4.1 Abstract 
 MOV10 is a putative RNA helicase that has yet to be demonstrated to show ribonucleic 
acid remodeling abilities. In this chapter, we begin the process of analyzing the molecular 
mechanism by which MOV10 interacts with RNA molecules through the use of single molecule 
total internal fluorescence microscopy (sm-TIRF). Here, we show that synthesized sc1 RNA is a 
suitable substrate for single molecule imaging and folds in a salt dependent manner.  We 
establish preliminary data to determine behavior of potential RNA targets for eventual study of 
how MOV10 acts on true RNA targets. 
 
4.2 Introduction 
 Helicases are important for many functions--from DNA repair and replication to 
translation at the RNA level. Domains and structures have been well studied and a number of 
crystal structures have been established for helicases such as T7 and Upf1[1-3]. Helicases have 
been extensively studied using single molecule techniques. For example, Hepatitis C virus 
helicase NS3 is a well characterized helicase that has benefited greatly from single molecule 
studies. Optical tweezers have been used to study the unwinding of RNA hairpin substrates as 
well as determining the unwinding and stepping velocity of the protein [4-6]. This chapter 
outlines the potential and lays the groundwork for future studies to further understand the 
molecular mechanism of MOV10 on RNA secondary structures.   
 FMRP binds RNA G quadruplexes, with sc1 as one of the model GQs that is bound with 
high affinity [7]. We recently identified it as an RNA substrate for MOV10 (Chapter 3), however 
the structure of the molecule was resolved by NMR [8], making this an ideal starting point to 
pursue single molecule studies.  Single molecule imaging is a powerful tool that allows us to 
visualize nuanced and unique events at the per-molecule level.  FRET energy transfers can be 
used to visualize changes in distance between the two fluorophores from a range of 20-80 
angstroms (reviewed in [9]). The resolution offered by these techniques offers science an 
amazing tool to study individual kinetic and structural changes, especially on RNA secondary 
structures such as G-quadruplexes [10].   
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4.3 Results:  
in vitro transcribed and end labeled RNAs are suitable for smFRET 
 Due to the length of the RNA constructs of PSD95, hASH1, sc1 and sc1 mut, it was 
necessary to in vitro transcribe and label molecules manually. Constructs were generated based 
on location of G quadruplexes and also the strength of GQs.  (Figure 1) and labeled.  RNAs were 
annealed to a biotinylated tether that contained the Cy5 dye, therefore annealed 
tether+synthesized RNA is visualized as yellow.  Annealed RNA migrated slower on an 
acrylamide gel compared to unannelead single stranded synthesized molecules indicating an 
increase in molecular weight.  
 We first analyzed the RNA molecules by smFRET to determine behavior in salt solution.  
Because these RNAs have never been previously studied, it was difficult to determine where the 
dye would be placed in addition to predicting how the molecules would behave at the single 
molecule level.  Based on previously published work, we developed sc1, sc1 mutant constructs, 
PSD-95 and hASH1 mRNA constructs that contained GQ forming sequences validated by QGRS. 
We expected these mRNAs to be loosely folded at low salt and tightly folded with increasing salt 
concentrations.  We tested sc1 RNA, titrating NaCl, KCl, and LiCl, which are known salts to 
stabilize and coordinate GQ formation [11].  In low salt solutions, the RNA molecules largely 
existed in low FRET states, ranging from 0.2-0.3, suggesting a loose and unstructured 
conformation. With increasing levels of monovalent cations, the population shifted to favor the 
high FRET state from 0.8-0.9, indicating that the two dyes are now in close proximity to each 
other (Fig 2).   
 We next performed salt titrations on the sc1 mutant, hASH1, and PSD-95 to determine 
whether the RNA constructs also behaved similarly to sc1.  Compared to sc1, sc1 mutant did not 
fold as efficiently, suggesting that the nucleotide substitutions significantly affected secondary 
structure and RNA folding (Fig 3a).  hASH1 GQs 1 and 2 demonstrated salt dependent folding.  
By 50mM KCl, the majority population of the RNA was in a high fret state (Fig 3b).  We 
anticipated the same to be true for PSD-95 however the construct selected did not successfully 
fold even in the presence of 300 mM salt.  This may be due to the length of the sequence, or the 
complexity of the secondary structure.   
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 sc1 RNA folds to high FRET in the presence of RGG peptide 
 Sc1 is an interesting molecule because it was initially found in a screen of high affinity 
binding RNAs to FMRP [12].  In the presence of the FMRP RGG box, the peptide suddenly 
snapped the RNA into a structured GQ [8].  We wanted to determine whether or not we could 
mimic this effect at the single molecule level, so we incubated 1mm minimal RGG peptide 
required for sc1 folding and found that the FMRP RGG box induced folding of sc1 RNA, even in 
low salt conditions.   
 We next determined the time scale by which binding of RGG peptide influenced sc1 
RNA folding.  In a brief time course experiment, we found that sc1 RNA became folded within 
30 seconds of peptide addition and remained folded for the remainder of the time course (Fig 4) 
suggesting a strong and stable association between the peptide and RNA.  
 
4.4 Discussion 
 These introductory studies demonstrate that single molecule FRET of MOV10 and 
associated mRNAs are a promising avenue of research.  Current studies of FMRP-mRNA 
interactions have been performed using bulk measurements and assays, making the analysis of 
individual molecule binding very difficult.  sc1 RNA has been analyzed by circular dichroism 
and also by NMR studies [8, 13].  We are the first to demonstrate sc1 folding efficiency in salt 
solutions as well as single molecule interactions between the FMRP RGG peptide and sc1 RNA. 
Additionally, we have demonstrated that potential targets that are recognized by MOV10 and 
FMRP are also viable targets for single molecule studies.   
 Obtaining sufficient quantities of purified FMRP and MOV10 would be next steps 
toward understanding how these proteins interact with target RNAs.   
 
Acknowledgements 
 Single molecule TIR experiments and data analysis were performed with the assistance of 
Helen Hwang in the Myong lab.  Typhoon imaging and RGG peptide was synthesized from the 
protein facilities at the University of Illinois.   
 
4.5 Experimental Procedures 
in vitro transcription constructs, labeling, and RGG peptide and MOV10 purification  
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DNA constructs were ordered from IDT 
sc1 wt: 
5’GCCTCGCTGCCGTCGCCCGCTGCGCAACCCGACCACTCCTTCCACACCGCAGCCCC
TATAGTGAGTCGTATTA3’ 
sc1 mut: 
5’GCCTCGCTGCCGTCGCCCGCTGCGCAACCCGACCACTGGTTCCACACCGCAGCCCC
TATAGTGAGTCGTATTA3’ 
hASH1: 
5’GCCTCGCTGCCGTCGCCACTCGCCCTCCCTGGCCGGATCCCTGTCGGTGCGCCTTC
CACGTTCCCTGGCCAGAAGCCCTATAGTGAGTCGTATTA3’ 
PSD-95: 
5’GCCTCGCTGCCGTCGCCCCAACCCCTGACCCTTTGCCCCCTCCACATTCCCCACTCC
CCAGACCCATCCCTCCCCTTTTCCCCCCTATAGTGAGTCGTATTA3’ 
 
RNA was transcribed using T7 RNA polymerase as per manufactures instructions. Transcribed 
RNA was labeled using the EndTag Nucle Acid Labeling system (Vector annealed by slow 
cooling from 95C at a 1:1.5 ratio of tether to synthesized RNA.  
 
Minimal RGG peptide was synthesized by the protein facilities at the University of Illinois 
Urbana Champaign Protein Services Facility and resuspended at 1uM in water.  The peptide 
sequence is the minimal RGG peptide established in [8].  
 
HEK293F cells were grown to 5x10^5 cells/mL and transfected with myc-MOV10 using PEI 
(Sigma).  24-48 hrs after transfection, cells were harvested and lysed and myc-MOV10 was 
immunoprecipitated using myc-conjugated agarose beads (Sigma) and eluted with myc peptide 
after immunoprecipitation.   
 
Single molecule imaging and experimental setup 
Slides were prepared as described in [14]. Briefly, quarts slides and coverslips were cleaned and 
treated with methanol, acetone, KOH, burned and treated with aminosilane followed by a coating 
of 3% biotin PEG and 97% PEG.  
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Heteroduplex RNA/DNA constructs were immobilized on the slide surface.  Unbound molecules 
were washed with buffer containing 1 mg/mL glucose oxidase, .4% (w/v) D glucose, 0.04 
mg/mL catalase, and 1% v/v 2- mercaptoethanol.  
Prism type total internal reflection microscopy was used to acquire single molecule FRET as 
described in [15]. A 532-nm Nd:YAG laser was guided through a prism to generate an 
evanescent field of illumination. A water-immersion objective was used to collect the signal and 
a 550-nm long pass filter was used to remove the scattered light. Cy3 signals were collected 
using a 630-nm dichroic mirror and sent to a charge-coupled device camera. Data were recorded 
with a time resolution of 100 ms as a stream of imaging frames and analyzed with scripts written 
in interactive data language. 
 
  
107 
 
4.6 Figures. 
 
 
Figure 4.1. Typhoon image of synthesized RNAs. Increasing concentrations of sc1 RNA 
facilitated more efficient annealing (yellow) of tether DNA (red) to the synthesized mRNA 
(green).   
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Figure 4.2. Salt titrations on sc1 RNA.  NaCl, KCl, and LiCl salt solutions were used titrated at 
10, 50, 150, and 300 mM concentrations.  High fret was demonstrated most efficiently with NaCl 
followed by KCl, and LiCl.   
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Figure 4.3. Salt titrations of synthesized RNA constructs.  A. sc1 folds in high salt 
concentrations, however sc1 mutant remains largely low-mid fret with a small high fret peak 
even in 300 mM KCl.  B. Synthesized hASH1 folds in the presence of salt, existing in largely 
high fret states at 50mM KCl.  PSD-95 however, did not fold successfully even in high salt 
concentrations.  
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Figure 4.4.  RGG peptide induces folding of sc1 RNA in low salt conditions. A.  The addition 
of 1uM RGG peptide induced folding of sc1 RNA at 1mM KCl salt solution. B. sc1 folding 
occurs within the first 30 seconds of RGG peptide addition.  
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Chapter 5. MOV10 in the 5’UTR 
 
 
5.1 Abstract 
 MOV10 was found to bind and regulate mRNAs through studies presented in chapter 3; 
however its role in the 5’UTR was not yet elucidated.   In this chapter, we describe a novel role 
for MOV10 in regulating translation of mRNA targets through modification of secondary 
structure.  hASH1 is an mRNA target bound and regulated by FMRP.  This upregulation is 
mediated through the 5’UTR and also dependent on the presence of MOV10.  
 
5.2 Introduction 
G-Quadruplexes in nucleic acids 
 G-quadruplexes (GQs) are very stable secondary structures formed by nucleic acids, 
formed by the stacking of guanine tretrads.  These bases bond in non-Watson Crick pairs, but 
rather through Hoogsteen base pairing where each guanine acts as a donor and acceptor for 
hydrogen bonds. G quadruplexes can also form between multiple strands making these inter- 
versus intra-molecular structures.  GQs are stabilized by monovalent cations, preferring K
+ 
< 
Na
+ 
< Li
+
[1].  GQs have been implicated in a number of regulatory functions from nuclear 
transcription to cytoplasmic translation.   
 
DNA G-Quadruplexes  
 In DNA, GQs are most familiarly present at the telomere, which is rich in hexameric 
TTAGGG repeats [2, 3], in addition to many promoter regions in DNA.  These molecules take 
on several conformations from parallel to anti-parallel, basket types to inter and intra molecular 
structures (reviewed in [4]).  This variability in sequence and structure makes G quadruplexes 
interesting secondary structures that act as regulatory switches in nucleic acids.   Telomeres form 
stable GQs and protect the end of chromosomes and inhibit the action of telomerase, which is 
activated in a large percentage of cancers.  Many cancers (expand a little more).  Additionally 
DNA GQs are involved in regulation of gene transcription.  Several loci are tightly regulated 
such as c-MYC, KRAS, and hTERT, where the prevalence of GQs within the promoter regions 
can regulate gene transcription [5, 6].  At the level of DNA, these secondary structures are 
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important for the first steps in regulation, potentially becoming novel therapeutic targets for 
diseases such as cancers [7].     
 
RNA G-Quadruplexes 
 RNA structures demonstrate more structural flexibility due to their single stranded nature 
and therefore can form more stable and stronger GQs [8]. In RNA molecules, GQs can serve as 
translational regulators acting both in the 3’and 5’UTRs as well as signals that may act as a 
localization signal as have been described for CamKII and PSD-95 [9].        
 In translation, the 5’UTR plays a variety of roles in initiation, scanning, and elongation. 
The presence of strong secondary structures near the 5’cap or even potentially masking the AUG 
start codon are all factors which may affect states of translation (reviewed in [10]). Some 
examples of strong secondary structure inhibiting translation have been demonstrated in NRAS, 
where GQ structures present closer to the 5’cap are more inhibitory compared to if they were 
located more centrally in the UTR [11, 12].  The same is true for a number of other genes such as 
the matrix metalloproteinase (MT3) and also BCL-2 [13, 14].  However, GQ structures may also 
play a role in facilitating translation by acting as an internal ribosome entry site (IRES), 
permitting cap-independent translation which is the case for VEGF, where a G quadruplex 
structure is important for facilitating translation [15].  These studies demonstrate that localization 
of the GQs in the 5’UTR play an important regulatory role in mRNAs.   
 Despite the prevalence of GQ structures throughout the cell, only a small handful of 
proteins have been demonstrated to specifically bind and unwind GQ secondary structure.  
RHAU, the RNA helicase associated with AU-rich elements is a DEAH-box RNA helicase that 
has been found to bind and also resolve G quadruplex RNA structures at the end of telomeres 
[16]. RHAU has also been published to resolve tetrameric G-quadruplexes as well as associate 
with a number of RNAs containing GQ sequences [17, 18].   
 
FMRP and GQs 
 FMRP binds and recognizes RNA GQ structures, sc1 being one example of a high 
affinity binder as was reviewed in Chapter 1.  An interesting target that FMRP binds and 
regulates its own transcript through GQs found in its own transcript, FMR1 [19].  The G-
quadruplex region of FMRP acts as an exonic splicing enhancer, regulating the splicing of exon 
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15 of the FMR protein, further describing important roles for both the GQ binding abilities of 
FMRP and also the secondary structure of the RNA.  FMRP, besides binding its own transcript, 
is also required for proper localization of two neuronal transcripts: PSD-95 and CAMKII 
mRNAs to the neurites [20]. PSD-95 and CAMKII have been well studied to be regulated and 
bound by FMRP [21-23]. These two mRNAs contain G quadruplex forming sequences as 
confirmed by reverse transcription and RNase protection assays. PSD-95 contained three tandem 
GQs while CAMKII only contained one, however removing these specific structures resulted in 
the loss of neurite localization of these transcripts.  
 
5.3 Results 
MOV10 associates with GQ containing sequences in the 5’UTR 
 In chapter 3, we found that MOV10 demonstrated specificity for GQ binding.  Co-
incidentally, this is a pattern we found in a number of the CLIP targets. What became interesting 
was the fact that MOV10 bound mRNA targets both in the 3’UTR as was studied in Chapter 3. 
While there were less targets bound in the 5’UTR, we found that of the 14 targets bound, 6 of 
them contained GQ forming sequences in the CLIP site, with STK11 containing three potential 
GQ forming patterns. Interestingly, the GQ containing sequences also had a high percentage of 
guanine composition compared to the non-GQ containing CLIP sites.  What was strikingly 
different between the two was that the average length of the 5’UTR was about 7 times longer in 
the GQ containing CLIP sites (1659.5 bases) compared to the non GQ containing CLIP sites in 
the 5’UTR (224.4 bases if PCDH19 is excluded) (Table 1).  This led us to further investigate the 
role of MOV10 in the 5’UTR. 
 
FMRP requires MOV10 for upregulation of hASH1 mRNA 
 In 2009, FMRP was found to bind and regulate hASH1 mRNA through its 5’UTR [24].   
hASH1, which is a transcription factor for development, was an interesting target due to the 
unusual length of the 5’UTR (571 nucleotides)  as well as the presence of many different motifs: 
AU rich regions, poly U tracts and two tandem GQ forming sequences located centrally in the 
UTR. We analyzed the full 5’UTR of hASH1 using QGRS and found two additional G 
quadruplexes located immediately 3’ to the cap, with GQ scores of 18 and 20, comparable to sc1 
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(Fig 1A).  We were interested in using hASH1 as a potential target for studying the role of 
FMRP and MOV10 binding on a true neuronal target.  
 FMRP has been demonstrated to bind and increase translational regulation of hASH1, 
however hASH1 binding was mediated through the U rich region, which we were able to 
reproduce (Fig 1b left).  Because MOV10 demonstrated GQ binding capabilities, we next sought 
to determine whether MOV10 had an impact on FMRP mediated translational upregulation.  We 
found that knockdown of MOV10 through siRNA treatment inhibited FMRP mediated 
upregulation, suggesting that FMRP somehow requires MOV10 to regulate hASH1 translation 
(Fig 1b).  Knockdown of MOV10 was efficient, indicating that the effects were mediated by the 
presence of MOV10.  Similar to other brain mRNA targets such as CALM3 and eEF2, hASH1 
may potentially require MOV10 to recruit the target to FMRP.   
 We next sought to determine the RNA binding capabilities of MOV10.  MOV10 binds 
sc1 RNA with specificity, since disruption of the GQ prevented MOV10 association (Chapter 3).  
MOV10 demonstrated RNA binding ability of sc1 but not sc1 mutant in 5, 75, and 200mM KCl 
solutions (Fig 2a).  Interestingly, MOV10 also demonstrated specificity for poly G beads, but not 
poly A, C, or U (Fig 2b).  hASH1 mRNA was in vitro synthesized and also assessed for MOV10 
binding.  We found that full length, middle GQ deletion, and poly U tract (DU) all demonstrated 
binding by MOV10.  The polyU deletion (DU) demonstrated less binding by FMRP as was 
described [24].  Both MOV10 and FMRP specifically bound sc1 but not the sc1 mutant (Fig 2c). 
 The presence of two tandem GQs present near the 5’cap of the hASH1.  Because FMRP 
bound hASH1 in the polyU tract, and MOV10 demonstrated specificity for GQ structures, we 
hypothesized that MOV10 could bind and unwind these two tandem structures to facilitate 
ribosome loading and scanning on the hASH1 mRNA.  Thus, we removed the GQs and 
compared translation in a reticulolysate assay to determine whether the tandem GQs were in fact 
inhibitory for translation.  Upon removal of the GQs, we found that translation of the luciferase 
construct increased, suggesting that the quadruplexes were inhibiting translation (Fig 3b).    
 
5.4 Discussion 
 The work presented in this chapter introduces a role for MOV10 in the 5’UTR, especially 
in mRNA transcripts that have long and highly structured 5’UTRs.  Many GQ binding proteins 
have not yet been elucidated, yet these mRNA secondary structures are prevalent throughout the 
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genome and transcriptome.  Taken together, these studies suggest a potential role for MOV10 in 
the 5’UTR.  MOV10 has been published to be involved in miRNA pathways and also associated 
with Ago2 [25-27], a role in translation regulation through the 5’UTR has not been well studied. 
Here, we demonstrate a novel role for translational regulation by MOV10. 
 These studies suggest that MOV10 is involved in binding of long, highly structured 
5’UTRs and may act by facilitating unwinding of secondary structure or somehow enhancing 
translation of target mRNAs.  
 
5.5 Experimental Procedures 
Western blots  
The anti-FMRP antibody 1a obtained from Jean-Louis Mandel at the Institute of Genetics in 
Illkirch, France, was used as a hybridoma supernatant for immunoblotting at a 1/10 dilution. 
Anti-MOV10 antibody (Bethyl) was used at a 1:1000 dilution for 1 hr at rt or over night at 4C. 
Antibody reactivity was visualized using an anti-mouse horseradish-peroxidase conjugate 
(Jackson Laboratories). 
Capture assays  
RNA capture assays were performed as described [28].  Briefly, purified protein was incubated 
with biotin-tagged RNA at 30C for 20 minutes and captured on streptavidin coated beads 
(Dynabeads) for 2 hours at room temperature.  Beads were washed and boiled in SDS sample 
buffer and analyzed by western blot.  
Luciferase Transfections and Luciferase assays.   
HEK293T cells were plated in 24 well plates at 10^4 cells/well and transfected using PEI 
(Sigma), and MOV10 specific siRNA or irrelevant siRNA.  24 hrs post transfection, cells were 
retransfected with siRNA, 100 ng/well luciferase construct and 10ng/well renilla.  24 hrs after, 
cells were lysed and assayed for luciferase activity.  For in vitro transcription translation 
reactions, hASH1 5’UTR-Luc was transcribed using the MEGAscript T7 kit (Invitrogen).  
Translation assay was performed as described in [29].  Luciferase assay was carried out using the 
dual-luciferase reporter assay kit (Promega) as per manufacturer’s instructions and measured on 
a LUMIstar OPTIMA luminometer, programmed with OPTIMA softer v 2.00.  
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5.6 Tables and Figures 
 
 
Figure 5.1.  FMRP requires MOV10 to upregulate translation of hASH1 mRNA.  A. GQRS 
analysis of the 571nt 5’UTR of hASH1 mRNA.  B.  FMRP upregulates translation of hASH1 
reporter constructs.  Knockdown of MOV10 blocks translation upregulation mediated by FMRP.  
p<0.05 is denoted by (*), p<0.01 is denoted by (**).  C.  Western blot confirmation of 
transfections.  
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Figure 5.2.  MOV10 and FMRP specifically bind similar RNAs.  A.  MOV10 binds sc1 but 
not sc1 mutant in RNA capture assays of varying KCl concentrations.  B.  MOV10 demonstrates 
specificity for polyG sequences.  C.  MOV10 and FMRP capture assays demonstrate hASH1 
binding.  FMRP binding is reduced in the DU mutant, and FMRP and MOV10 binding is 
disrupted in the sc1 mutant construct.   
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Figure 5.3. 5’ tandem hASH1 GQ(1,2) sequence is translationally inhibitory. A. hASH1 
sequence of the two tandem 5’ GQ sequences, highlighting the GQ forming sequences identified 
by QGRS.  B.  in vitro translation assay of the full length hASH1 (FL) compared to the GQ 
deletion.  p<0.05 is denoted by (*).  
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Table 5.1.  Analysis of 5’UTR CLIP targets bound by MOV10.  
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Chapter 6. Conclusions and future directions 
 
 
6.1 Concluding remarks 
 Through my thesis work, I have demonstrated in Chapter 2 that FMRP binds nascent 
mRNAs in the nucleus and subsequently exports these target mRNAs out into the cytoplasm.  
Through a novel mechanism described in Chapter 3, we show that MOV10, a putative RNA 
helicase and Argonaute2 are key components in regulation of FMRP bound mRNA targets.  As 
these cellular mechanisms were slowly revealed, we began to observe RNA and protein behavior 
by turning to single molecule resolution in Chapter 4.  Through these efforts, we have traveled 
with an mRNA molecule from transcription until its fate in degradation and sought to clarify the 
means by which these proteins work together to make a cell function normally. In chapter 5, I 
discuss preliminary work demonstrating a role for MOV10 in the 5’UTR.  These UTRs are long 
and highly structured suggesting a necessity for unwinding assistance. Future experiments to 
better understand the mechanism of how FMRP utilizes associated proteins to function as a 
regulator of translation are presented in this chapter. 
 
Summary 1.   
 In chapter 2, we discuss the mechanism by which FMRP binds and recognizes its mRNA 
transcript.  Through the use of the Xenopus laevis oocyte system, we were able to demonstrate 
that FMRP binds and recognizes nascent mRNA transcripts in the nucleus.  FMRP bound in the 
nucleus is then exported via Tap/Nxf1 and then processed further in the cytoplasm for 
subsequent translation.  
 
Future work for Summary 1.  
1. Identify the mechanism by which FMRP is selected for import into the nucleus. 
Currently, it is largely unknown is how FMRP shuttles in and out of the nucleus.  We 
demonstrated that Tap/Nxf1 is important for nuclear export; however import into the nucleus 
is understudied.  The nuclear localization sequence of FMRP is a non-canonical NLS that 
contains many lysines and arginines [1, 2].  Recently, in a screen of developmentally delayed 
males without CGG repeat expansion, the traditional mechanism of FMR1 silencing, several 
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mutations in the FMR1 gene were identified.  One notable mutation was found within the 
nuclear localization sequence, R138Q, which alters a conserved residue in the FMRP NLS, 
highlighting the importance of nuclear shuttling by FMRP for normal cognitive development 
[3]. Understanding what proteins are important for nuclear import as well as determining 
which splice variants of FMRP are involved in nuclear shuttling is a largely understudied 
area of research.   
2. Determine methylation patterns important for binding nascent mRNA in the nucleus. 
Previous work has found that FMRP is methylated on several arginine residues, and that 
FMRP methylation confers some amount of RNA specificity as well as association of FMRP 
with mRNAs and polyribosomes [4, 5]. Further exploring the role of these post translational 
modifications and its impact on RNA binding specificity through polysome and binding 
assays would be an interesting area to study.  While it is understood that FMRP is an RNA 
binding protein, determining how FMRP binds and recognizes specific mRNA targets 
whether it be for nuclear export, translational regulation, or mRNA localization is a key to 
understanding the complex disease process of fragile X syndrome.    
 
Summary 2.   
 Chapter 3 described a novel associated protein, MOV10—a largely uncharacterized 
putative RNA helicase, and how the two proteins bind and regulate translation of mRNA through 
competition or facilitation of Ago2 mediated miRNA regulation. We found that FMRP and 
MOV10 both associated in similar granules in brain and in cells and are also present along 
polyribosomes.  Interestingly, we also discovered that MOV10 specifically recognizes and binds 
RNA GQs, which is a structure that FMRP has also been published to bind.  We found that 
mRNA targets specifically bound by MOV10 had different fates in MOV10 knockdown versus 
overexpression.  These changes in fate were namely mediated through the 3’UTR, suggesting a 
role in miRNA mediated regulation.   
 We identified several mRNAs that contained MOV10 CLIP sites which overlapped with 
Ago2 binding sites suggesting a miRNA mediated mechanism of regulation. We found that the 
presence of secondary structure, namely G-Quadruplexes may act as a landing site for MOV10 
such that binding of MOV10 would compete with Ago2 if the binding sites were overlapping.  In 
these cases, MOV10 acted in a protective manner, preventing Ago2 from mediating RNA 
125 
 
degradation.  In the absence of MOV10, Ago2 binding sites were then exposed, allowing Ago2 
to destabilize the bound mRNA.   
 
Future work for summary 2.   
1. Identify how GQ sequences influence MOV10 binding and Ago2 mediated translational 
regulation. We described a few targets, Phact2, TGFB1, MAZ, and SamHD1, which are 
regulated by miRNAs and also affected by the presence or absence of MOV10. Further 
pursing the role of miRNAs and MOV10 binding would be interesting to develop by 
performing mutational analysis to tease apart whether it is the presence of secondary 
structure or miRNA binding that is influencing regulation.  One interesting target that is 
currently being pursued is MAZ which we found to be a candidate example of MOV10 
inhibiting miRNA mediated degradation that contains both miRNAs and GQs in the CLIP 
binding sites.  By mutating the seed sequence without hindering the GQ s and also disrupting 
the GQ structure without affecting the miRNA binding site for MAZ as well as other mRNA 
targets would help us determine how MOV10 either helps or inhibits regulation.   
2. Determine whether phosphorylation status of FMRP influences MOV10 association. 
FMRP, in addition to being methylated on arginine residues, is also phosphorylated on serine 
residues, influencing translation state of polyribosomes [6].  In addition to modulating 
translation, phosphorylation also acts as a switch to modulate its interactions with Dicer [7].  
Determining whether or not MOV10 association with FMRP is dependent on 
phosphorylation status of FMRP would shed light on what aspects of miRNA mediated 
regulation the two proteins are involved.  
 
Summary 3.   
 In this chapter, we begin to explore the possibility of studying MOV10 and FMRP 
together at the single molecule level to begin understanding the dynamics between FMRP and 
MOV10.  We found that the model GQ sc1 folded in a salt dependent manner that was detectable 
by FRET.  These studies have never before been validated at the single molecule level, making 
this an exciting avenue to explore.  We tested the G quadruplexes of hASH1 in addition to PSD-
95 and also the sc1 mutant.  Similar to previous work [8], sc1 became highly structured in the 
presence of the RGG peptide as observed by single molecule FRET.   
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Future work for summary 3.   
1. Demonstrate MOV10 helicase activity using smFRET. Chapter 4 sets the groundwork to 
study the physical mechanism by which MOV10 interacts with target mRNAs.  We now 
have identified the specific region that MOV10 binds from CLIP data presented in Chapter 3.  
These sequences can be analyzed for GQ formation and subsequently used to design novel 
RNA substrates to be used for single molecule studies. Because we now know specific 
targets, we can use these mRNAs to answer the questions: Does MOV10 translocate or 
unwind GQ structures?  Does MOV10 require ATP? Does MOV10 displace FMRP on 
mRNA? Amongst other questions. To begin these studies, full length functional MOV10 
must be available, either through the use of insect cell purification or mammalian cell 
purification, which has been marginally successful.  While mammalian cell purification has 
been successful in generating enough full length protein to pursue basic capture assays, it has 
not been in high enough concentrations to successfully perform the proposed studies.  
Through purification via sf9 insect cell culture, full length protein may be generated for these 
studies.   
2. How do FMRP and MOV10 act together on the same mRNA? FMRP and MOV10 bind 
similar mRNA targets, however the proximal localization and binding specificities of these 
two proteins on the same mRNA is unknown.  By also isolating full length FMRP through 
insect cultures, we can begin to answer the question of whether or not binding of the two 
proteins act cooperatively or competitively.  
 
Summary 4.   
 Chapter 5 describes a role for MOV10 in the 5’UTR.  We studied the role of MOV10 in 
the miRNA pathway, regulating protein and mRNA levels via the 3’UTR.  However, MOV10 
plays a broad role in the fate of RNAs as it is implicated in the infectivity and also replication of 
RNA viruses such as HIV and Hepatits D [9-11] and recently also involved in long the inhibition 
of retrotransposon LINE1 mobility throughout the genome as well as associating with the LINE1 
RNA and regulating its stability [12].   From analysis of the CLIP data, we found several mRNA 
targets where MOV10 bound the 5’UTR.  Interestingly, those CLIP targets that contained a GQ 
within the binding site also had very long 5’UTRs. hASH1, a recently described target of FMRP, 
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also had a long 5’UTR as well as two tandem GQ sequences at the 5’cap, which are inhibitory 
for translation.   
 
Future work for summary 4. 
1. Does MOV10 affect translation initiation and efficient ribosome loading on highly 
structured 5’UTRs? MOV10 demonstrated an interesting pattern of binding in the 5’UTR.  
CLIP targets that contained GQ sequences in the binding site had considerably longer 5’UTR 
lengths than the mRNA targets that did not contain GQ sequences in the CLIP site.  
Understanding the role of MOV10 in influencing protein levels of each target and separating 
the role of MOV10 in the 5’UTR from the 3’UTR is a promising area of study. Currently, 
there are few known helicases that modify GQ structures on mRNAs, and identifying the 
mechanism by which MOV10 influences secondary structure on target mRNAs will elucidate 
a novel mechanism of translational regulation that is independent of the miRNA pathway.  
 
Conclusions 
 FMRP is important for proper neuronal development as the absence of FMRP is the cause 
of  fragile X syndrome.  By understanding how FMRP binds and recognizes target mRNAs as 
well as identifying mechanisms by which FMRP and associated proteins are capable of exerting 
regulatory functions on these mRNA targets is a first step towards more clearly understanding 
the disease process of fragile X.  
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6.2 Figures. 
 
Figure 6.1.  Model summary of work performed.    
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